CA2074180A1 - Thiazole derivatives - Google Patents
Thiazole derivativesInfo
- Publication number
- CA2074180A1 CA2074180A1 CA002074180A CA2074180A CA2074180A1 CA 2074180 A1 CA2074180 A1 CA 2074180A1 CA 002074180 A CA002074180 A CA 002074180A CA 2074180 A CA2074180 A CA 2074180A CA 2074180 A1 CA2074180 A1 CA 2074180A1
- Authority
- CA
- Canada
- Prior art keywords
- ppm
- omega
- substituted
- multiplet
- singlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 13
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims abstract description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000002357 guanidines Chemical class 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 6
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 4
- 230000000172 allergic effect Effects 0.000 claims abstract description 4
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 238000006698 hydrazinolysis reaction Methods 0.000 claims abstract description 3
- 125000005544 phthalimido group Chemical group 0.000 claims abstract description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- -1 5H-dibenzo-[a,d]-cyclohepten-5-yl group Chemical group 0.000 claims description 14
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 102000003710 Histamine H2 Receptors Human genes 0.000 claims description 6
- 108090000050 Histamine H2 Receptors Proteins 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 238000005893 bromination reaction Methods 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- 238000003756 stirring Methods 0.000 description 35
- 238000001816 cooling Methods 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 25
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 229960004132 diethyl ether Drugs 0.000 description 19
- 238000002844 melting Methods 0.000 description 19
- 230000008018 melting Effects 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 101150056637 Hrh2 gene Proteins 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 101150041968 CDC13 gene Proteins 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 230000008570 general process Effects 0.000 description 8
- 229910010272 inorganic material Inorganic materials 0.000 description 8
- 239000011147 inorganic material Substances 0.000 description 8
- 150000003557 thiazoles Chemical class 0.000 description 8
- IFPPZTSKNBSMHN-UHFFFAOYSA-N 2-(3-bromo-4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(Br)C(=O)C)C(=O)C2=C1 IFPPZTSKNBSMHN-UHFFFAOYSA-N 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- 229960000443 hydrochloric acid Drugs 0.000 description 7
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 7
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical compound C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 6
- LHVRFUVVRXGZPV-UHFFFAOYSA-N 5-(2-aminoethyl)-4-methyl-2-thiazolamine Chemical compound CC=1N=C(N)SC=1CCN LHVRFUVVRXGZPV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000000543 Histamine Receptors Human genes 0.000 description 6
- 108010002059 Histamine Receptors Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- FWNCNQDIENYPDJ-UHFFFAOYSA-N 2-(4-hydroxybutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCO)C(=O)C2=C1 FWNCNQDIENYPDJ-UHFFFAOYSA-N 0.000 description 5
- DPATUMDQWSJANG-UHFFFAOYSA-N 2-(4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(=O)C)C(=O)C2=C1 DPATUMDQWSJANG-UHFFFAOYSA-N 0.000 description 5
- HVVRQUYSKYIOJV-UHFFFAOYSA-N 2-(5-oxohexyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCC(=O)C)C(=O)C2=C1 HVVRQUYSKYIOJV-UHFFFAOYSA-N 0.000 description 5
- CZGOECYPTLSLNI-UHFFFAOYSA-N 6-bromohexan-2-one Chemical compound CC(=O)CCCCBr CZGOECYPTLSLNI-UHFFFAOYSA-N 0.000 description 5
- 239000002178 crystalline material Substances 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- KZZIVOLMJPSDEP-UHFFFAOYSA-N 1-[3-(4-fluorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1h-imidazol-5-yl)propyl]guanidine Chemical compound C=1N=CNC=1CCCN=C(N)NCCC(C=1N=CC=CC=1)C1=CC=C(F)C=C1 KZZIVOLMJPSDEP-UHFFFAOYSA-N 0.000 description 4
- SUALZDCPKLVMJL-UHFFFAOYSA-N 5-(3-aminopropyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCCC1=CN=C(N)S1 SUALZDCPKLVMJL-UHFFFAOYSA-N 0.000 description 4
- NFHWLPHEKVZKQU-UHFFFAOYSA-N 5-(3-aminopropyl)-4-methyl-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.CC=1N=C(N)SC=1CCCN NFHWLPHEKVZKQU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 150000002541 isothioureas Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KKKXIWVOUGTUNV-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-(3,3-diphenylpropyl)guanidine 2,4,6-trinitrophenol Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 KKKXIWVOUGTUNV-UHFFFAOYSA-N 0.000 description 3
- WNNXALBEELVCMI-UHFFFAOYSA-N 2-bromo-5-(1,3-dioxoisoindol-2-yl)pentanal Chemical compound C1=CC=C2C(=O)N(CCCC(Br)C=O)C(=O)C2=C1 WNNXALBEELVCMI-UHFFFAOYSA-N 0.000 description 3
- BHCHUXXNTHWMGJ-UHFFFAOYSA-N 4-(3-aminopropyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCCC1=CSC(N)=N1 BHCHUXXNTHWMGJ-UHFFFAOYSA-N 0.000 description 3
- WMJZCJDWHBNSLB-UHFFFAOYSA-N 5-(1,3-dioxoisoindol-2-yl)pentanal Chemical compound C1=CC=C2C(=O)N(CCCCC=O)C(=O)C2=C1 WMJZCJDWHBNSLB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 2
- GZOILRFVMJAQBC-UHFFFAOYSA-N 2-(3-bromo-4-hydroxybutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(Br)CO)C(=O)C2=C1 GZOILRFVMJAQBC-UHFFFAOYSA-N 0.000 description 2
- PTPZBCHKQSHXQZ-UHFFFAOYSA-N 2-(4-bromo-3-oxobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(=O)CBr)C(=O)C2=C1 PTPZBCHKQSHXQZ-UHFFFAOYSA-N 0.000 description 2
- PSKJVCNFAMZUFJ-UHFFFAOYSA-N 2-(5-bromo-4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(=O)CBr)C(=O)C2=C1 PSKJVCNFAMZUFJ-UHFFFAOYSA-N 0.000 description 2
- AEQXSCZKSNBLQW-UHFFFAOYSA-N 2-(5-hydroxypentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCO)C(=O)C2=C1 AEQXSCZKSNBLQW-UHFFFAOYSA-N 0.000 description 2
- VQVGTGLZTBUTQY-UHFFFAOYSA-N 2-[2-(4-methyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound N1=CSC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1C VQVGTGLZTBUTQY-UHFFFAOYSA-N 0.000 description 2
- DNLARIARHLWZRF-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCCN=C(N)NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C DNLARIARHLWZRF-UHFFFAOYSA-N 0.000 description 2
- SLTUYEGLKJHGHO-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-cyano-3-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCCN=C(NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)NC#N)=C1C SLTUYEGLKJHGHO-UHFFFAOYSA-N 0.000 description 2
- BNCFKRVOUNWXAY-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN)C1=CC=C(Cl)C(Cl)=C1 BNCFKRVOUNWXAY-UHFFFAOYSA-N 0.000 description 2
- LZHGBLUAJMICBZ-UHFFFAOYSA-N 5-(2-aminoethyl)-1,3-thiazol-2-amine Chemical compound NCCC1=CN=C(N)S1 LZHGBLUAJMICBZ-UHFFFAOYSA-N 0.000 description 2
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004384 Histamine H3 receptors Human genes 0.000 description 2
- 108090000981 Histamine H3 receptors Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- TZNOQFCVOYXCAM-UHFFFAOYSA-N [amino(ethylsulfanyl)methylidene]-(3,3-diphenylpropyl)azanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC[NH+]=C(N)SCC)C1=CC=CC=C1 TZNOQFCVOYXCAM-UHFFFAOYSA-N 0.000 description 2
- 229950009330 arpromidine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940005991 chloric acid Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SWXXKWPYNMZFTE-UHFFFAOYSA-N (c-ethylsulfanylcarbonimidoyl)azanium;bromide Chemical compound Br.CCSC(N)=N SWXXKWPYNMZFTE-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- ONTXCMXICQNNNO-UHFFFAOYSA-N 2-(3-oxobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(=O)C)C(=O)C2=C1 ONTXCMXICQNNNO-UHFFFAOYSA-N 0.000 description 1
- TVAQJFUNSFVSGP-UHFFFAOYSA-N 2-(4-methyl-1,3-thiazol-5-yl)ethanamine Chemical compound CC=1N=CSC=1CCN TVAQJFUNSFVSGP-UHFFFAOYSA-N 0.000 description 1
- IPOCGIVMVZXNBQ-UHFFFAOYSA-N 2-[2-(2-amino-1,3-thiazol-4-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1 IPOCGIVMVZXNBQ-UHFFFAOYSA-N 0.000 description 1
- LNPILXRCRBMXCD-UHFFFAOYSA-N 2-[2-(2-amino-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound S1C(N)=NC=C1CCN1C(=O)C2=CC=CC=C2C1=O LNPILXRCRBMXCD-UHFFFAOYSA-N 0.000 description 1
- QAZIDPZKBKDKHT-UHFFFAOYSA-N 2-[3-(2-amino-1,3-thiazol-4-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC(CCCN2C(C3=CC=CC=C3C2=O)=O)=C1 QAZIDPZKBKDKHT-UHFFFAOYSA-N 0.000 description 1
- FQEIHIVPLCDSGY-UHFFFAOYSA-N 2-[3-(2-amino-1,3-thiazol-5-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC=C1CCCN1C(=O)C2=CC=CC=C2C1=O FQEIHIVPLCDSGY-UHFFFAOYSA-N 0.000 description 1
- YQGBOZHSFVQEPQ-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.N1=C(N)SC(CCCN2C(C3=CC=CC=C3C2=O)=O)=C1C YQGBOZHSFVQEPQ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- XMNSDCYVLIMUOT-UHFFFAOYSA-N 2-bromo-4-(1,3-dioxoisoindol-2-yl)butanal Chemical compound C1=CC=C2C(=O)N(CCC(Br)C=O)C(=O)C2=C1 XMNSDCYVLIMUOT-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GQAFTAYUUOBTRK-UHFFFAOYSA-N 3,5,5-trimethyl-4H-pyrazole-1-carbothioamide Chemical compound CC1=NN(C(N)=S)C(C)(C)C1 GQAFTAYUUOBTRK-UHFFFAOYSA-N 0.000 description 1
- CSJHCQDRYAUEQH-UHFFFAOYSA-N 3-(4-methyl-1,3-thiazol-2-yl)propan-1-amine;dihydrochloride Chemical compound Cl.Cl.CC1=CSC(CCCN)=N1 CSJHCQDRYAUEQH-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WMXADABRNBNSJC-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)butanal Chemical compound C1=CC=C2C(=O)N(CCCC=O)C(=O)C2=C1 WMXADABRNBNSJC-UHFFFAOYSA-N 0.000 description 1
- IOXZFXWMILDPTH-UHFFFAOYSA-N 4-(3-aminopropyl)-1,3-thiazol-2-amine Chemical compound NCCCC1=CSC(N)=N1 IOXZFXWMILDPTH-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NQUYKSNCKIXTQF-UHFFFAOYSA-N 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.CC=1N=C(N)SC=1CCN NQUYKSNCKIXTQF-UHFFFAOYSA-N 0.000 description 1
- BHBQCSAJEKMSPN-UHFFFAOYSA-N 5-(2-bromoethyl)-4-methyl-1,3-thiazole;hydrobromide Chemical compound Br.CC=1N=CSC=1CCBr BHBQCSAJEKMSPN-UHFFFAOYSA-N 0.000 description 1
- RIOVLKQWIKRBIB-UHFFFAOYSA-N 5-(3-aminopropyl)-4-methyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1CCCN RIOVLKQWIKRBIB-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- NEDHHMJNFMKLBT-UHFFFAOYSA-N C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCCC1=CC=CC=C1 Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCCC1=CC=CC=C1 NEDHHMJNFMKLBT-UHFFFAOYSA-N 0.000 description 1
- SMIKUIMODNMCCG-UHFFFAOYSA-N C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC=C(N1)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC=C(N1)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 SMIKUIMODNMCCG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100021757 E3 ubiquitin-protein ligase RNF135 Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 101001106984 Homo sapiens E3 ubiquitin-protein ligase RNF135 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000529738 Picris Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OLHQOJYVQUNWPL-UHFFFAOYSA-N dimaprit Chemical class CN(C)CCCSC(N)=N OLHQOJYVQUNWPL-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- LUOYACCQSOFAAA-UHFFFAOYSA-N ethyl 6-methyl-3,6-dihydro-2h-pyran-5-carboxylate Chemical compound CCOC(=O)C1=CCCOC1C LUOYACCQSOFAAA-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000003386 histamine H2 receptor agonist Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- MURRAGMMNAYLNA-UHFFFAOYSA-N impromidine Chemical compound N1C=NC(CSCCNC(N)=NCCCC=2NC=NC=2)=C1C MURRAGMMNAYLNA-UHFFFAOYSA-N 0.000 description 1
- 229950005073 impromidine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VKFHVRIEURVUHM-UHFFFAOYSA-N n-(diphenoxymethylidene)benzamide Chemical compound C=1C=CC=CC=1C(=O)N=C(OC=1C=CC=CC=1)OC1=CC=CC=C1 VKFHVRIEURVUHM-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
A N-[.omega.-(thiazol-4 or 5-yl)alkyl]isourea, isothiourea of a guanidine derivative with formula (II) and a N-(.omega.-substituted alkyl)-N'-substituted-N''-[.omega.-(thiazol-4 or 5-yl)alkyl]-guanidine with formula (III), a process for the preparation of said compounds by ring closure of a 2-bromo-.omega.-phthalimidoalkanal, or of a 3-bromo or 1-bromo .omega.-phthalimidoalkan-2-one with thioformamide, an alkylthioamide or thiourea followed by hydrazinolysis or hydrolysis of the resulting phthalimido derivates and medicaments containing said derivatives with formulas (II) and (III) and use of said medicaments for the treatment of congestive heart diseases or for the treatment of allergic disorders.
Description
91/1~57 PCT~NL91/~W~8 ~"~ - 1 - 207'~t8',0'~
.. . . .
,........ . :
'' ' ' '' - , .
New thiazole derivatives.
~., The invention relates to new thiazole derivatives which are:
a. a N-~-(thiazol-4 or s-yl)alkyl]isourea~ isothiourea or a guanidine derivative with formula 2, wherein X represents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represQnts a nitrogen atom and Y represents a sulphur atom, n i8 1-6, R1 represents a hydrogen atom or a straight or branch~d alkyl group w$th 1-4 carbon atoms and R2 repre-sents a- hydrogen atom,~a straight or-.branched aLkyl group with 1-4 carbon atoms or an amino group, Z represents a sulphur atom, an oxygen atom or a NH-group respectively, R3 represents a hydrogen atom, a phenyl or.an alkyl group with 1-4 carbon atoms respectively and R4 repre~ents a hydrogen atom, a cyano or a benzoyl group respectively;
b. a N-(~-substituted alkyl)-N~-sub~tituted-Nn-~-(thiazol-4 or-5-yl)alkyl]guanidine with formula 3, wherein X repre~ents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represents a nitrogen atom and Y repre~ents a ~ulphur atom, n is 1-6, Rl represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R2 repre-sents a hydrogen atom, a straight or branched alkyl group with 1-4 carbon atoms or an amino group, R4 represents hydrogen, a cyano or a benzoyl group respectively, m is 1,2 or 3, A represents a sulphur or an oxygen atom, a -CH2- or ,; - ................. , - . ., . : -: - ` ' ` :' ' . , ~.' ', ':', '. ' ' ' , ' " ' ' ' ' , . , ' ' , - ' . - ' ' ': , .
', ' . ~ ' ' ' , .': . : ~ : ' WO 91/1~57 -2- PCT/NL91/~008~
.. . . .
,........ . :
'' ' ' '' - , .
New thiazole derivatives.
~., The invention relates to new thiazole derivatives which are:
a. a N-~-(thiazol-4 or s-yl)alkyl]isourea~ isothiourea or a guanidine derivative with formula 2, wherein X represents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represQnts a nitrogen atom and Y represents a sulphur atom, n i8 1-6, R1 represents a hydrogen atom or a straight or branch~d alkyl group w$th 1-4 carbon atoms and R2 repre-sents a- hydrogen atom,~a straight or-.branched aLkyl group with 1-4 carbon atoms or an amino group, Z represents a sulphur atom, an oxygen atom or a NH-group respectively, R3 represents a hydrogen atom, a phenyl or.an alkyl group with 1-4 carbon atoms respectively and R4 repre~ents a hydrogen atom, a cyano or a benzoyl group respectively;
b. a N-(~-substituted alkyl)-N~-sub~tituted-Nn-~-(thiazol-4 or-5-yl)alkyl]guanidine with formula 3, wherein X repre~ents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represents a nitrogen atom and Y repre~ents a ~ulphur atom, n is 1-6, Rl represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R2 repre-sents a hydrogen atom, a straight or branched alkyl group with 1-4 carbon atoms or an amino group, R4 represents hydrogen, a cyano or a benzoyl group respectively, m is 1,2 or 3, A represents a sulphur or an oxygen atom, a -CH2- or ,; - ................. , - . ., . : -: - ` ' ` :' ' . , ~.' ', ':', '. ' ' ' , ' " ' ' ' ' , . , ' ' , - ' . - ' ' ': , .
', ' . ~ ' ' ' , .': . : ~ : ' WO 91/1~57 -2- PCT/NL91/~008~
2 0 7 ~ 8'~
a -CH= group respectively and Q represents a R-substituted diphenylmethyl group or a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or Q
represents a nitrogen atom substituted with Q1 and Q2, whe-rein Q1 and Q2 represent whether or not symmetrical R-substituted (~-)phenyl(alkyl) groups, or Q represents a R-substituted (~-)phenyl(alkyl) group or Q represents a whether or not symmetrical mono-or disubstituted methylidene fragment, wherein R' represents a R-substituted (10,11-dihy-dro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or R' represents two whether or not symmetrically with R
substituted phenyl, groups, wherein R represents hydro gen, alkyl, alkoxy, amino, mono- or dialkylamino, guanidino, nitro, carboxy, carbalkoxy, halogen (fluoro, chloro, bromo, iodo), mono-, di- and trihalogenmethyl or -methoxy (halogen =
fluoro, chloro, bromo) etc., while in addition the R-substi-tuted phenyl rings may be replaced by a (heterocyclic)(aromatic) ring whether or not R-substituted or by a combina-tion of a (condensed) (aromatic) (heterocyclic) R-substituted ring with one or more (condensed) (aromatic) (heterocyclic) rings whether or not symmetrically R-substituted.
Possible present R-substituted (condensed) (heterocyclic) (aromatic) rings are for example: 2-, 3-, 4-pyridyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-[dihydro]pyridyl, 4- or 5-imida-zolyl, 2-, 4- or 5-thiazolyl, 2- or 3-furyl, 2- or 3-thienyl, dihydropyridazinon-2 or 6-yl, 2-benzoimidazolyl, etc.
.
The invention also relates to the acid addition salts of the - compounds with the formulas 2 and 3.
Histamine receptors are classified according to the present knowledge into three categories which are described, mainly for historical reasons, with the qualifications of Hl-, H2-and H3-receptor.
Each of these classes of receptors presumably has its own and biologically specific function, in as far as they are present and dependent on the location of such a receptor type in the -WO91/1~57 ~3~ PCTtNL91/~N~X
organism involved. 2'dt'~4`'1~8 0 In circumstances where a failure of the normal physiological system has occurred a treatment with endogenous or exogenous compounds may be necessary which may stimulate (agonistic activity) or inhibit (antagonistic activity) the receptor system.
From the above follows the great importance of compounds capable to agonize or to antagonize in a selective way the different classes of histamine receptors.
It is important to be able to dispose of selective histamine receptor active compounds in order to discriminate between the different receptor types not only from a scientific (pharma-cological) point of view, but also on therapeutic respect notably the stimulation of the histamine H2-receptor offers wide perspectives for the treatment of congestive heart diseases, accompanied by heart failure, and certain allergic disorders so that there exists a large interest from within the pharmaceutical industry for the development and application o~ sQlective, histamlne H2-receptor active, compounds.
Impromidine (5), described by G.J. Durant et al. in Nature 276, p.403-405 (1978) and Dimaprint (6), de6cribed by C.~.
Ganellin in Pharmacology of Histamine Receptors, p.40-44 (1982), publishers Wright.PSG., exhibit a moderately to fairly high affinity for the histamine H2-receptor.
N-(~-substituted alkyl)-N'-[imidazol-4-yl]alkyl)guanidines with formula 7, as described in the Dutch patent application 86 01585, and Arpromidine (8) and analogues, as described by A.~uschauer in J.Med.Chem. 32, p.l963-1970 (1989) on the contrary exhibit a high to very high affinity for the H2-receptor.
Both ~mpromidine (5), the most active guanidine derivatives of formula 7 and Arpromidine (8) all contain under physiolo-gical circumstances a protonated N-~3-(imidazol-4-yl)propyl]-guanidine fragment.
This fragment, which has been described as SK~F 91486 (9) by M.E. Paxsons et al. in Agents and Actions 5, p.464 (1975) has - . . -, . .
. ' .
' ~ ' , .
wosl/l~s7 -4- PCT/NL91/00008 2 0; 7 4 1.,8 0 been considered in the literature as an element essential for the activity of this type of compounds on the H2-receptor as 5 described by A.Buschauer in J.Med.Chem. 32, p.1963-1970 (1989).
Further substitution at one of the free nitrogen atoms or the guanidine function of this basic element may be applied in order to increase the affinity for the H2-receptor and/or to introduce a possibly wanted additional biological activity such as: antagonism of the H1-receptor, as described by G.J.Sterk et al. in Eur.J.Med.Chem. 22, p.427-432 (1987) and the Dutch patent application 86 0158S, calciumantagonism as illustrated by the guanidine derivative (10) described by 15 V.Pfahlert et al., in Arch.Pharm. 338, R49 (1988), or phosp-hodiesterase ;inhibition as described in the European patent application 0310737 and illustrated by the guanide derivative (11) .
Likewise in these compounds (lo and 11), the imidazole moiety can be replaced by a (substituted)aminothiazole.
Thus the invention also relates to a process for the prepara-tion of a ~-aminoalkylthiazole derivative in which one prepa-res a histamine H2-receptor active compound, whether or not in combination with an additionally wanted biological activi-ty, by preparing from a compound with formula 1 or its acid addition salt a compound with a substituted 4- or 5-(~-thiazolyl-alkyl)guanidine fragment.
Examples of such compounds are the compounds with formulas 2 and 3 and their acid addition salts.
Additional substitution at the other nitrogen atom may be applied in order to change the activity for the H2-receptor into an antagonistic activity.
Although thus far a large number of (substituted) analogues of histamine, in which the imidazole term has been replaced by another heterocyclic ring system, has been described in the literature, for a review of which reference may be made to C.R. Ganellin in Pharmacology of Histamine Receptors, p.21-31 (1982), publishers Wright.PSG, none of the mentioned analogues displays an acti~ity at the H2-receptor which is f091/10657 -5- PCT/NL91/ ~ i 8 0 comparable to that of histamine. Only M.Impicciatore et al~
report in Agents and Actions, 20, p.3-4 (1987) about 2-amino-5-(2-aminoethyl)-thiazole, which according to these authors is able to stimulate through an indirect pathway the histam-ine H2-receptor (as determined on the fundus of . the guinea pig). In Il Farmaco Ed.Sci., 40 (6), p.483-498 (1986) T.Vita-li et al. describe this same 2-amino-5-(2-aminoethyl)thiazole reporting that this compound exhibits an activity on the right atrium of the guinea pig of 0.3% relative to the activity of histamine whereas this activity is related to the inotropic effect.
A new series of substituted ~-(thiazol-4 or 5-yl)alkyl derivatives has now been discovered which display a very selective and high histamine H2-receptor activity on the right atrium of the guinea pig, namely the above mentioned compounds with formulas 1-4 and their acid addition salts.
All this is clearly illustrated by a characteristic represen-tative of the 4- or 5-(~-aminoalkyl)thiazoles reported under formula 1, viz. the 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) which is essentially a substituted sulphur analogue of the endogenous histamine (13) or which alternatively may be ,considered as a closed ring analogue of dimaprit (6).
25,~,Whereas ,endogenous,histamine (13),is able to,stimulate all previously mentioned-types of histamine receptors, the 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) can be displaced competitatively by cimetidine, while the intrinsic activity (related to the chronotropic effect) is equal to that of histamine, thus rendering it to be a full agonist for the H2-receptor with an activity twice as high as that of histamine.
The 2-amino-5-(3-aminopropyl)-4-methylthiazole (26b) is a full H2-receptor agonist with an activity 30 times as high as that of the corresponding 4(5)-3-aminopropyl)-imidazole.
35 The 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) shows how-ever contrary to histamine (13), in the testing systems used not a single activity towards the Hl and H3-receptors.
The essence of the invention now relates to the replacement of the N-~3-(imidazol-4-yl)propyl]guanidine fragment (9) f rom the previously mentioned different classes of H2-receptor ' ..
: . , :' . ', : ' " WO~ ~57 -6- PCTlNL91/ ~
- active compounds with i.a. other combined Hl-receptor antago-nistic, calcium antagonistic, phosphodiesterase inhibitory activity etc, by the more H2-receptor specific and more acti~e N-[3-(substituted thiazol-4 or 5-yl)propyl]guanidine frag~ents. The thiazole derivatives with formulas 2-4 thus obtained show a high to very high activity on the H2-recep-tor.
The 4- or 5-(~-aminoalkyl)thiazole derivatives mentioned in the introduction with`formula 1 may be obtained using a pro-cess not previously described in the literature in high yields by ring closure of a 2-bromo-~-phthalimidoalkanal (18), a 3-bromo-~-phthalimidoalkan-2-one (24) or a 1-bromo-~-phthalimidoalkan-2-one (27) with thioformamide, an alkylthio-amide or thiourea in dimethylformamide under mild conditions, followed by hydrazinolysis or hydrolysis with diluted hydro-chloric acid of the resulting phthalimido derivatives (19, 25 or 28) as depicted in reaction schemes A and B.
As will be evident from reaction scheme A one uses as star-ting materials for the preparation of the 2-bromo-~-phthali-midoalkanals (18) ~-phthalimidoalkanols ~16) which may be obtained using processes known from the literature. Conversi-on of these ~-phthalimidoalkanols (16) into the corresponding aldehydes (17)--is being carried out according to a general method using oxalylchloride/dimethylsulphoxyde, followed by proton abstraction with a mild base such as triethylamine followed by hydrolysis with water as described by X.Omura et al. in Tetrahedron 34, p. 1651-1660 (1978).
Subsequently the desired 2-bromo-~-phthalimidoalkanalS (18) are obtained in almost quantitative yield by selective ~-bromination of the obtained ~-phthalimidoalkanals (17) with bromine in carbon tetrachloride.
The preparation of the 3-bromo-~-phthalimidoalkan-2-ones (24) as indicated in reaction scheme (B) takes place by selective bromination with bromine in carbon tetrachloride of the cor-responding ~-phthalimidoalkan-2-ones (23) which may be obtai-ned according to a process described in the Dutch patent WO91i1~57 ~7~ PCT/NL91/~W~8 ~- 2 ~,,Z ~.?8 at~ ~
application 8800998 in which the necessary 1-bromo-~-phthali-midoalkan-2-ones (27) have been descri~ed as well. The neces-sar~ ~-haloketones (22) which are to be used for the prepara-tion of the 1- and 3-bromo-~-phthalimidoalkan-2-ones (24 and 27) are either commercially available or may be obtained in good yield according to a process described in the literature such as for example the process described in the Dutch patent application 65 11581. -The N-[~-(thiazol-4 or 5-yl)alkyl]isourea or isothiourea derivatives with formula 2 are obtained by reaction of a 4-or 5~ aminoalkyl)thiazole with formula 1, with a dialkyl-N-cyano-iminodithiocarbonate, a diphenyl-N-cyanocarbonimidate or a diphenyl-N-benzoylcarbonimidate respectively in a suitable solvent according t~ methods known from the litera-ture and as indicated in reaction scheme C.
The corresponding N-[~-(thiazol-4 or 5-yl)alkyl]guanidine derivatives are obtained by reacting a 4- or 5-(~-aminoal-kyl)thiazole with formula 1 together with a S-alkylisothiou-ronium derivative. The N-[~-~thiazol-4 or 5-yl)alkyl]isourea or isothiourea derivatives thu5 obtained (32) are condensed with a suitable amine (33). The N-(~-substituted alkyl)-N'-subtltuted-N"-t~-(thiazol-4 or 5-yl)alkylguanidines with formula 3 (34) thus obtained are puri~ied and subjected to a mild hydrolysis in diluted hydrochloric acid following which the resulting N-(~-substituted alkyl)-N'-[~-(thiazol-4 or 5-yl)alkyl~-guanides with formula 4 (3S) can be obtained in good yield eventually after conversion to a suitable acid addition salt.
Alternatively the desired N-(~-substituted alkyl)-N'substitu-ted-Nn-~-(thiazol-4 or 5-yl)alkyl]guanidines with formula 3 may be obtained by reacting a 4- or 5-(~-aminoalkyl)thiazole with formula 1 together with the corresponding N-(~-substitu-ted alkyl)isourea or isothiourea derivatives (36) according to methods known from the literature and as indicated in reaction scheme D or by condensation of a 4- or 5-(~-aminoal-kyl)thiazole with formula 1 with a N-(~-substitUted alkyl)-S-alkylthiouronium derivative (41) as indicated in reaction ., , - , . . . .
., , . -.,~. . ~ . -, ': ' , , ' . ' ' ;' ' ~ ' . ' WO91/1065? -~- PCT/NL91/~W~8~ -2 b~ 4~8 ~`
sche~e E.
The invention also relates to a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formulas 2-3 or an acid addition salt thereof. One may use the~compounds or -the medicaments according to the invention for the treatment of congestive heart diseases whether or not accompanied by hear failure or for the treatment of allergic disorders.
~. . .
... . . ..
.
.. .
.
,'. ' ' ~ ~ ":', ' ' ' ~.
WO91/1~57 PCT/NL91J00008:, t~'',', .
2b~7~86~
The invention is illustrated by the following examples:
A11 the chemicals and solvents used are com~ercial-ly available unless stated otherwise.
Melting points were determined by a Mettler FP 5 5 device for the determination of melting points.
1H-NMR-spectra were determined with a Bruker .. . .. . .. . .. .
WH-90 spectrophotometer and the chemical shifts S(in ppm) with tetramethylsilane as reference.
Mass spectra are determined on a Varian Mat CH5 10 spectrometer or on a Mat 90 (Finnigan Mat, San Jose, U.S.A.).
Histamine H2-activity was determined on the ~ight-side atrium of the guinea pig as described by G.J. Sterk et al in Eur.J.Med. Chem.,19, p. 545-550 (1984).
Example I
hthalimido-1-alkanols (16) General process:
A mixture of 148 g (1 mole) of particulated phthalic anhydride (15) and 1 mole of a desired w -amino-l- ;
alkanol is heated under nitrogen with stirring 20 at circa 80C. After starting the exothermal reaction with which the temperature is rising to circa 140 C, there is heated at 140 C for three hours.After cooling the reaction mixture until circa 80C the viscous mass - is poured out in.icewater with stirring. Subsequently 25 it is extracted with chloroform and the collected chloroform-phases are extracted with a 5%-aqueous sodiumhydrogen carbonate solution, thereafter it is washed three times with demineralized water. After drying on anhydrous sodium sulfate and fil- ~-tration the chloroform phase is h~h-vacuum concentrated.
Thus there were obtained:
a.4=ohthalim~do-1-butanol (16a) in 91% yield, from phthalic anhydride and 4-aminobutanol. .
-: . . , ., . . : . ~ . , i. ~ . , .~ : .
: ., : , , - . , : . ;
, : : . .. '` : : .
: .:: .: . . , -: . ~
,, . . : ~: .
WO91/1~57 PCTJNL91/~08 20~7~,418 0?~ ~
- 10 ~
1~NMR ~CDC13): 1.38-1.90 ppm.,multiplet, 4H; 2.53 ppm, single~, lH; 3.51-3.83 ppm, multiplet, 4H; 7.58-7.94 ppm, multiplet, 4H.
b. 5-phthalimido-1-pentanol (16b) in 85% yield, __ ___________ from phtalic anhydride and 5-amino pentanol.
H-NMR (CDC~13j: 1.23-1.90 ppm., multiplet, 6H; 2.36 ppm., singlet, lH; 3.59 ppm.,triplet (J=5.4 Hz), 2H;
a -CH= group respectively and Q represents a R-substituted diphenylmethyl group or a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or Q
represents a nitrogen atom substituted with Q1 and Q2, whe-rein Q1 and Q2 represent whether or not symmetrical R-substituted (~-)phenyl(alkyl) groups, or Q represents a R-substituted (~-)phenyl(alkyl) group or Q represents a whether or not symmetrical mono-or disubstituted methylidene fragment, wherein R' represents a R-substituted (10,11-dihy-dro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or R' represents two whether or not symmetrically with R
substituted phenyl, groups, wherein R represents hydro gen, alkyl, alkoxy, amino, mono- or dialkylamino, guanidino, nitro, carboxy, carbalkoxy, halogen (fluoro, chloro, bromo, iodo), mono-, di- and trihalogenmethyl or -methoxy (halogen =
fluoro, chloro, bromo) etc., while in addition the R-substi-tuted phenyl rings may be replaced by a (heterocyclic)(aromatic) ring whether or not R-substituted or by a combina-tion of a (condensed) (aromatic) (heterocyclic) R-substituted ring with one or more (condensed) (aromatic) (heterocyclic) rings whether or not symmetrically R-substituted.
Possible present R-substituted (condensed) (heterocyclic) (aromatic) rings are for example: 2-, 3-, 4-pyridyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-[dihydro]pyridyl, 4- or 5-imida-zolyl, 2-, 4- or 5-thiazolyl, 2- or 3-furyl, 2- or 3-thienyl, dihydropyridazinon-2 or 6-yl, 2-benzoimidazolyl, etc.
.
The invention also relates to the acid addition salts of the - compounds with the formulas 2 and 3.
Histamine receptors are classified according to the present knowledge into three categories which are described, mainly for historical reasons, with the qualifications of Hl-, H2-and H3-receptor.
Each of these classes of receptors presumably has its own and biologically specific function, in as far as they are present and dependent on the location of such a receptor type in the -WO91/1~57 ~3~ PCTtNL91/~N~X
organism involved. 2'dt'~4`'1~8 0 In circumstances where a failure of the normal physiological system has occurred a treatment with endogenous or exogenous compounds may be necessary which may stimulate (agonistic activity) or inhibit (antagonistic activity) the receptor system.
From the above follows the great importance of compounds capable to agonize or to antagonize in a selective way the different classes of histamine receptors.
It is important to be able to dispose of selective histamine receptor active compounds in order to discriminate between the different receptor types not only from a scientific (pharma-cological) point of view, but also on therapeutic respect notably the stimulation of the histamine H2-receptor offers wide perspectives for the treatment of congestive heart diseases, accompanied by heart failure, and certain allergic disorders so that there exists a large interest from within the pharmaceutical industry for the development and application o~ sQlective, histamlne H2-receptor active, compounds.
Impromidine (5), described by G.J. Durant et al. in Nature 276, p.403-405 (1978) and Dimaprint (6), de6cribed by C.~.
Ganellin in Pharmacology of Histamine Receptors, p.40-44 (1982), publishers Wright.PSG., exhibit a moderately to fairly high affinity for the histamine H2-receptor.
N-(~-substituted alkyl)-N'-[imidazol-4-yl]alkyl)guanidines with formula 7, as described in the Dutch patent application 86 01585, and Arpromidine (8) and analogues, as described by A.~uschauer in J.Med.Chem. 32, p.l963-1970 (1989) on the contrary exhibit a high to very high affinity for the H2-receptor.
Both ~mpromidine (5), the most active guanidine derivatives of formula 7 and Arpromidine (8) all contain under physiolo-gical circumstances a protonated N-~3-(imidazol-4-yl)propyl]-guanidine fragment.
This fragment, which has been described as SK~F 91486 (9) by M.E. Paxsons et al. in Agents and Actions 5, p.464 (1975) has - . . -, . .
. ' .
' ~ ' , .
wosl/l~s7 -4- PCT/NL91/00008 2 0; 7 4 1.,8 0 been considered in the literature as an element essential for the activity of this type of compounds on the H2-receptor as 5 described by A.Buschauer in J.Med.Chem. 32, p.1963-1970 (1989).
Further substitution at one of the free nitrogen atoms or the guanidine function of this basic element may be applied in order to increase the affinity for the H2-receptor and/or to introduce a possibly wanted additional biological activity such as: antagonism of the H1-receptor, as described by G.J.Sterk et al. in Eur.J.Med.Chem. 22, p.427-432 (1987) and the Dutch patent application 86 0158S, calciumantagonism as illustrated by the guanidine derivative (10) described by 15 V.Pfahlert et al., in Arch.Pharm. 338, R49 (1988), or phosp-hodiesterase ;inhibition as described in the European patent application 0310737 and illustrated by the guanide derivative (11) .
Likewise in these compounds (lo and 11), the imidazole moiety can be replaced by a (substituted)aminothiazole.
Thus the invention also relates to a process for the prepara-tion of a ~-aminoalkylthiazole derivative in which one prepa-res a histamine H2-receptor active compound, whether or not in combination with an additionally wanted biological activi-ty, by preparing from a compound with formula 1 or its acid addition salt a compound with a substituted 4- or 5-(~-thiazolyl-alkyl)guanidine fragment.
Examples of such compounds are the compounds with formulas 2 and 3 and their acid addition salts.
Additional substitution at the other nitrogen atom may be applied in order to change the activity for the H2-receptor into an antagonistic activity.
Although thus far a large number of (substituted) analogues of histamine, in which the imidazole term has been replaced by another heterocyclic ring system, has been described in the literature, for a review of which reference may be made to C.R. Ganellin in Pharmacology of Histamine Receptors, p.21-31 (1982), publishers Wright.PSG, none of the mentioned analogues displays an acti~ity at the H2-receptor which is f091/10657 -5- PCT/NL91/ ~ i 8 0 comparable to that of histamine. Only M.Impicciatore et al~
report in Agents and Actions, 20, p.3-4 (1987) about 2-amino-5-(2-aminoethyl)-thiazole, which according to these authors is able to stimulate through an indirect pathway the histam-ine H2-receptor (as determined on the fundus of . the guinea pig). In Il Farmaco Ed.Sci., 40 (6), p.483-498 (1986) T.Vita-li et al. describe this same 2-amino-5-(2-aminoethyl)thiazole reporting that this compound exhibits an activity on the right atrium of the guinea pig of 0.3% relative to the activity of histamine whereas this activity is related to the inotropic effect.
A new series of substituted ~-(thiazol-4 or 5-yl)alkyl derivatives has now been discovered which display a very selective and high histamine H2-receptor activity on the right atrium of the guinea pig, namely the above mentioned compounds with formulas 1-4 and their acid addition salts.
All this is clearly illustrated by a characteristic represen-tative of the 4- or 5-(~-aminoalkyl)thiazoles reported under formula 1, viz. the 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) which is essentially a substituted sulphur analogue of the endogenous histamine (13) or which alternatively may be ,considered as a closed ring analogue of dimaprit (6).
25,~,Whereas ,endogenous,histamine (13),is able to,stimulate all previously mentioned-types of histamine receptors, the 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) can be displaced competitatively by cimetidine, while the intrinsic activity (related to the chronotropic effect) is equal to that of histamine, thus rendering it to be a full agonist for the H2-receptor with an activity twice as high as that of histamine.
The 2-amino-5-(3-aminopropyl)-4-methylthiazole (26b) is a full H2-receptor agonist with an activity 30 times as high as that of the corresponding 4(5)-3-aminopropyl)-imidazole.
35 The 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) shows how-ever contrary to histamine (13), in the testing systems used not a single activity towards the Hl and H3-receptors.
The essence of the invention now relates to the replacement of the N-~3-(imidazol-4-yl)propyl]guanidine fragment (9) f rom the previously mentioned different classes of H2-receptor ' ..
: . , :' . ', : ' " WO~ ~57 -6- PCTlNL91/ ~
- active compounds with i.a. other combined Hl-receptor antago-nistic, calcium antagonistic, phosphodiesterase inhibitory activity etc, by the more H2-receptor specific and more acti~e N-[3-(substituted thiazol-4 or 5-yl)propyl]guanidine frag~ents. The thiazole derivatives with formulas 2-4 thus obtained show a high to very high activity on the H2-recep-tor.
The 4- or 5-(~-aminoalkyl)thiazole derivatives mentioned in the introduction with`formula 1 may be obtained using a pro-cess not previously described in the literature in high yields by ring closure of a 2-bromo-~-phthalimidoalkanal (18), a 3-bromo-~-phthalimidoalkan-2-one (24) or a 1-bromo-~-phthalimidoalkan-2-one (27) with thioformamide, an alkylthio-amide or thiourea in dimethylformamide under mild conditions, followed by hydrazinolysis or hydrolysis with diluted hydro-chloric acid of the resulting phthalimido derivatives (19, 25 or 28) as depicted in reaction schemes A and B.
As will be evident from reaction scheme A one uses as star-ting materials for the preparation of the 2-bromo-~-phthali-midoalkanals (18) ~-phthalimidoalkanols ~16) which may be obtained using processes known from the literature. Conversi-on of these ~-phthalimidoalkanols (16) into the corresponding aldehydes (17)--is being carried out according to a general method using oxalylchloride/dimethylsulphoxyde, followed by proton abstraction with a mild base such as triethylamine followed by hydrolysis with water as described by X.Omura et al. in Tetrahedron 34, p. 1651-1660 (1978).
Subsequently the desired 2-bromo-~-phthalimidoalkanalS (18) are obtained in almost quantitative yield by selective ~-bromination of the obtained ~-phthalimidoalkanals (17) with bromine in carbon tetrachloride.
The preparation of the 3-bromo-~-phthalimidoalkan-2-ones (24) as indicated in reaction scheme (B) takes place by selective bromination with bromine in carbon tetrachloride of the cor-responding ~-phthalimidoalkan-2-ones (23) which may be obtai-ned according to a process described in the Dutch patent WO91i1~57 ~7~ PCT/NL91/~W~8 ~- 2 ~,,Z ~.?8 at~ ~
application 8800998 in which the necessary 1-bromo-~-phthali-midoalkan-2-ones (27) have been descri~ed as well. The neces-sar~ ~-haloketones (22) which are to be used for the prepara-tion of the 1- and 3-bromo-~-phthalimidoalkan-2-ones (24 and 27) are either commercially available or may be obtained in good yield according to a process described in the literature such as for example the process described in the Dutch patent application 65 11581. -The N-[~-(thiazol-4 or 5-yl)alkyl]isourea or isothiourea derivatives with formula 2 are obtained by reaction of a 4-or 5~ aminoalkyl)thiazole with formula 1, with a dialkyl-N-cyano-iminodithiocarbonate, a diphenyl-N-cyanocarbonimidate or a diphenyl-N-benzoylcarbonimidate respectively in a suitable solvent according t~ methods known from the litera-ture and as indicated in reaction scheme C.
The corresponding N-[~-(thiazol-4 or 5-yl)alkyl]guanidine derivatives are obtained by reacting a 4- or 5-(~-aminoal-kyl)thiazole with formula 1 together with a S-alkylisothiou-ronium derivative. The N-[~-~thiazol-4 or 5-yl)alkyl]isourea or isothiourea derivatives thu5 obtained (32) are condensed with a suitable amine (33). The N-(~-substituted alkyl)-N'-subtltuted-N"-t~-(thiazol-4 or 5-yl)alkylguanidines with formula 3 (34) thus obtained are puri~ied and subjected to a mild hydrolysis in diluted hydrochloric acid following which the resulting N-(~-substituted alkyl)-N'-[~-(thiazol-4 or 5-yl)alkyl~-guanides with formula 4 (3S) can be obtained in good yield eventually after conversion to a suitable acid addition salt.
Alternatively the desired N-(~-substituted alkyl)-N'substitu-ted-Nn-~-(thiazol-4 or 5-yl)alkyl]guanidines with formula 3 may be obtained by reacting a 4- or 5-(~-aminoalkyl)thiazole with formula 1 together with the corresponding N-(~-substitu-ted alkyl)isourea or isothiourea derivatives (36) according to methods known from the literature and as indicated in reaction scheme D or by condensation of a 4- or 5-(~-aminoal-kyl)thiazole with formula 1 with a N-(~-substitUted alkyl)-S-alkylthiouronium derivative (41) as indicated in reaction ., , - , . . . .
., , . -.,~. . ~ . -, ': ' , , ' . ' ' ;' ' ~ ' . ' WO91/1065? -~- PCT/NL91/~W~8~ -2 b~ 4~8 ~`
sche~e E.
The invention also relates to a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formulas 2-3 or an acid addition salt thereof. One may use the~compounds or -the medicaments according to the invention for the treatment of congestive heart diseases whether or not accompanied by hear failure or for the treatment of allergic disorders.
~. . .
... . . ..
.
.. .
.
,'. ' ' ~ ~ ":', ' ' ' ~.
WO91/1~57 PCT/NL91J00008:, t~'',', .
2b~7~86~
The invention is illustrated by the following examples:
A11 the chemicals and solvents used are com~ercial-ly available unless stated otherwise.
Melting points were determined by a Mettler FP 5 5 device for the determination of melting points.
1H-NMR-spectra were determined with a Bruker .. . .. . .. . .. .
WH-90 spectrophotometer and the chemical shifts S(in ppm) with tetramethylsilane as reference.
Mass spectra are determined on a Varian Mat CH5 10 spectrometer or on a Mat 90 (Finnigan Mat, San Jose, U.S.A.).
Histamine H2-activity was determined on the ~ight-side atrium of the guinea pig as described by G.J. Sterk et al in Eur.J.Med. Chem.,19, p. 545-550 (1984).
Example I
hthalimido-1-alkanols (16) General process:
A mixture of 148 g (1 mole) of particulated phthalic anhydride (15) and 1 mole of a desired w -amino-l- ;
alkanol is heated under nitrogen with stirring 20 at circa 80C. After starting the exothermal reaction with which the temperature is rising to circa 140 C, there is heated at 140 C for three hours.After cooling the reaction mixture until circa 80C the viscous mass - is poured out in.icewater with stirring. Subsequently 25 it is extracted with chloroform and the collected chloroform-phases are extracted with a 5%-aqueous sodiumhydrogen carbonate solution, thereafter it is washed three times with demineralized water. After drying on anhydrous sodium sulfate and fil- ~-tration the chloroform phase is h~h-vacuum concentrated.
Thus there were obtained:
a.4=ohthalim~do-1-butanol (16a) in 91% yield, from phthalic anhydride and 4-aminobutanol. .
-: . . , ., . . : . ~ . , i. ~ . , .~ : .
: ., : , , - . , : . ;
, : : . .. '` : : .
: .:: .: . . , -: . ~
,, . . : ~: .
WO91/1~57 PCTJNL91/~08 20~7~,418 0?~ ~
- 10 ~
1~NMR ~CDC13): 1.38-1.90 ppm.,multiplet, 4H; 2.53 ppm, single~, lH; 3.51-3.83 ppm, multiplet, 4H; 7.58-7.94 ppm, multiplet, 4H.
b. 5-phthalimido-1-pentanol (16b) in 85% yield, __ ___________ from phtalic anhydride and 5-amino pentanol.
H-NMR (CDC~13j: 1.23-1.90 ppm., multiplet, 6H; 2.36 ppm., singlet, lH; 3.59 ppm.,triplet (J=5.4 Hz), 2H;
3.67 ppm., triplet (J=7.2 Hz), 2H; 7.58-7.92 ppm., multiplet, 4H.
10 ExamDle II
_ ____ ___ a. 4-Phthalimido-l-butanol (16b) __ ____________ __
10 ExamDle II
_ ____ ___ a. 4-Phthalimido-l-butanol (16b) __ ____________ __
4-Phthalimido-l-butanol (16b) can, if desired, also be obtained in the following way:
A mixture of 100 g (0.92 mole) of 4-chloro-1-butanol, 15 135.5 g (0,92 mole) phthalimid and 1Z7 g (0.92 mole particulated anhydroùs potassium carbonate in circa 500 ml dry dimethylformamide is refluxed under nitrogèn for 12 hours. After cooling the reaction mixture the inorganic salts- are filtered off 20 and the precipitateisrinsed with a.little cold methanol, subsequently the filtrate is vacuum concentrated.
To the residue obtainedcirca 250 ml of ethyl-acetate is added and after standing over night at 5C
the resulting residue is removed by filtration.
25 The filtrate is vacuum concentrated and the residue is taken up in circa 200 ml chloroform. After extraction with a 5%-aqueous sodium hydrogencarbonate solution there i5 extracted a few times in demineralized water.
The chloroform phase is dried on anhydrous potassium car-30 bonate, filtered and vacuum concentrated.
' ~ . ', , ' , , :
.
.- . ,, :
.. ,.' ' . . : . .
'.'. ' ' '' . . ' ' , ''''. '. . . " ' WO91/1~57 PCTtNL91/~W~8 ~.,, Yield 95%. The so obtained 4-phthalimido-1-butanol is identical to the product obtained by the general process for the ~ -phthalimido-1-alkanols as described in example I. After prolonged standing the viscous oil crystallized.
Melting point 47-~9 C.
Example III -~-phthalimido-l-alkanals (17) .
The preparation of the ~-phthalimido-1-alkanals (17) 10 occurs analogous to the method as described by K.Omura et al in Tetrahedron, 34, pages 1651-1660 (1978) for the preparation of aldehydes from aliphatic or benzylic alcohols.
General process: -To a solution of 63.5 g (0.5 mole) oxalylchloride in circa 15 1000 ml dry dichloromethane in.a nltrogen atmosphere with vigcroug stirring at -50C a solution of 83 g (1.06 mole) of dry dimethylsulfoxide in circa 200 ml of dry dichloromethane is dropwise added at such a rate.that the temperature is maintained at -50C. After the addition the 20 stirring is continued for 15 minutes, subsequently a solution of 0.40 mole of an appropriate ~ -phthalimido-1-alkanol (16) in circa 400 ml of dry dichloromethane is dropwise added at such a rate that the temperature is maintained at -50C.
.After the addition the stirring is continued at -50C for 25 30 minutes, subsequently 222 g (2.20 mole) of triethylamine .
is added thereto. Subsequently the cooling is removed and the reaction mixture is slowly brought with ~tirring at room temperature, thereafter circa 1250 ml of demineralized water :~is added. After stirring for 30 minutes at room temperature ;~;30 the organic phase is removed* and extracted with demineralized water to neutral reaction. The organic phase is subsequently . ~ . . . ~ : .
. .
' : - : ,.
- . . - :
:' ' . ' : ' ' -:: - . .
: ' :
W091/1~57 PCT/NL91/~W~8 f320~80 lZ - ~ ~
dried on anhydrous sodium sulfate, filtered and vacuum con-centrated. The viscous oil obtained is kept in nitrogen at-mosphere and is used without any further purification for the preparation of the corresponding 2-bromo-c~phthalimido-alkanales (18).
~ Nota bene: All the actions are carried out as much as possible in a nitrogen atmosphere to prevent oxidation of , the aldehydes obtained by atmospherical oxygen. I
Thus there were obtained:
10 a. ~-phthalimido-l-butanal (17a) in 80% yield, from 4-phthal-imidobutanol.
H-NMR (CDCl3): 1.80-2.19 ppm., multiplet, 2H; 2.S6 ppm., triplet (J=7.4 Hz), 2H; 3.74 ppm, triplet (J=6.8 Hz, 2H;
7.52-7.93 ppm., multiplet, 4H; 9.74 ppm., singlet, lH.
15 b. 5-phthalimido-1-pentanal (17b) in 85% yield, from
A mixture of 100 g (0.92 mole) of 4-chloro-1-butanol, 15 135.5 g (0,92 mole) phthalimid and 1Z7 g (0.92 mole particulated anhydroùs potassium carbonate in circa 500 ml dry dimethylformamide is refluxed under nitrogèn for 12 hours. After cooling the reaction mixture the inorganic salts- are filtered off 20 and the precipitateisrinsed with a.little cold methanol, subsequently the filtrate is vacuum concentrated.
To the residue obtainedcirca 250 ml of ethyl-acetate is added and after standing over night at 5C
the resulting residue is removed by filtration.
25 The filtrate is vacuum concentrated and the residue is taken up in circa 200 ml chloroform. After extraction with a 5%-aqueous sodium hydrogencarbonate solution there i5 extracted a few times in demineralized water.
The chloroform phase is dried on anhydrous potassium car-30 bonate, filtered and vacuum concentrated.
' ~ . ', , ' , , :
.
.- . ,, :
.. ,.' ' . . : . .
'.'. ' ' '' . . ' ' , ''''. '. . . " ' WO91/1~57 PCTtNL91/~W~8 ~.,, Yield 95%. The so obtained 4-phthalimido-1-butanol is identical to the product obtained by the general process for the ~ -phthalimido-1-alkanols as described in example I. After prolonged standing the viscous oil crystallized.
Melting point 47-~9 C.
Example III -~-phthalimido-l-alkanals (17) .
The preparation of the ~-phthalimido-1-alkanals (17) 10 occurs analogous to the method as described by K.Omura et al in Tetrahedron, 34, pages 1651-1660 (1978) for the preparation of aldehydes from aliphatic or benzylic alcohols.
General process: -To a solution of 63.5 g (0.5 mole) oxalylchloride in circa 15 1000 ml dry dichloromethane in.a nltrogen atmosphere with vigcroug stirring at -50C a solution of 83 g (1.06 mole) of dry dimethylsulfoxide in circa 200 ml of dry dichloromethane is dropwise added at such a rate.that the temperature is maintained at -50C. After the addition the 20 stirring is continued for 15 minutes, subsequently a solution of 0.40 mole of an appropriate ~ -phthalimido-1-alkanol (16) in circa 400 ml of dry dichloromethane is dropwise added at such a rate that the temperature is maintained at -50C.
.After the addition the stirring is continued at -50C for 25 30 minutes, subsequently 222 g (2.20 mole) of triethylamine .
is added thereto. Subsequently the cooling is removed and the reaction mixture is slowly brought with ~tirring at room temperature, thereafter circa 1250 ml of demineralized water :~is added. After stirring for 30 minutes at room temperature ;~;30 the organic phase is removed* and extracted with demineralized water to neutral reaction. The organic phase is subsequently . ~ . . . ~ : .
. .
' : - : ,.
- . . - :
:' ' . ' : ' ' -:: - . .
: ' :
W091/1~57 PCT/NL91/~W~8 f320~80 lZ - ~ ~
dried on anhydrous sodium sulfate, filtered and vacuum con-centrated. The viscous oil obtained is kept in nitrogen at-mosphere and is used without any further purification for the preparation of the corresponding 2-bromo-c~phthalimido-alkanales (18).
~ Nota bene: All the actions are carried out as much as possible in a nitrogen atmosphere to prevent oxidation of , the aldehydes obtained by atmospherical oxygen. I
Thus there were obtained:
10 a. ~-phthalimido-l-butanal (17a) in 80% yield, from 4-phthal-imidobutanol.
H-NMR (CDCl3): 1.80-2.19 ppm., multiplet, 2H; 2.S6 ppm., triplet (J=7.4 Hz), 2H; 3.74 ppm, triplet (J=6.8 Hz, 2H;
7.52-7.93 ppm., multiplet, 4H; 9.74 ppm., singlet, lH.
15 b. 5-phthalimido-1-pentanal (17b) in 85% yield, from
5-phthalimidopentanol.
H-NMR (CDCl3): 1.50-1.92 ppm., multiplet, 4H; 2.41-2.66 ppm., multiplet, 2H 3.73 ppm., triplet (J=6.8 Hz), 2H; 7.62-7.94 ppm., multiplet, 4H, 9.75 ppm., triplet (J=0.6 Hz), lH.
20 Exam~`le IV ` ~ -2-Bromo-~-phthalimido-1-alkanals (18) General process:
To a solution of 0.5 mole of an appropriate ~ -phthalimido-l-alkanol (17) in circa 500 ml of tetrachlorocarbon in a 25 nitrogen atmosphere stirring vigorously 80 g (0.5 mole) of bromine is cautiously added at room temperature. After decolor-ation of the reaction mixture stirring is continued at room temperature for 2 hours. Subsequently circa lO0 ml of ~`' .
.;
: ' , . . .
.
~ . .
~, i ': `
, ,. ~ .
~' ' ..
WO91/10657 PCT/NL91/~X~8 ~"~ } ~ i`'.J
13- 2~74180 chloroform and 500 ml of demineralized water are added, thereafter stirring takes place i~ a nitrogen atmosphere for 30 minutes. The water pha$e is removed and the organic phase is washed in a nitrogen atmosphere with demineralized~water to neutral reaction. After drying on anhydrous sodium sulfate and filtration the organic phase is vacuum concentrated. The viscous oil obtained is used without any purification for the preparation of the corresponding 5~ phthalimidoalkyl thiazoles (19).
10 Thus there were obtained:
a. 2-Bromo-4-phthalimido-1-butanal (18a) in 78.5 % yield, from 4-phthalimido-1-butanal (17a).
H-NMR (CDCl3: 2.00-2.75 ppm., multiplet, 2H; 3.87 ppm., triplet (J=6.8 Hz), 2H; 4.40 ppm, double triplet (J1=7.2 Hz, 15 J2= 1.8 Hz), lH; 7.59-7.96 ppm., multiplet, 4H; 9.45 ppm., doublet (J=1.8 Hz), lH.
b. 2-bromo-5-phthalimido-1-pentanal (18b) in 68% yield, __ from 5-phthalimido-1-pentanal (17b) H-NMR (CDCl3): 1.76-2.10 ppm.; multiplet, 4H; 3.73 ppm., 20 triplet (J=6.3 Hz), 2H; 4.36 ppm., broad triplet, lH; 7.60-7.92 ppm., multiplet, 4H; 9.40 ppm., doublet (J=1.8 Hz),lH.
-Example V
5-(~-phthalimidoalkyl)thiazoles (19) General process:
25 To a solution of 0.1 mole of an appropriate crude 2-bromo-phthalimido-1-alkanal (18) in circa 100 ml of dry dimethyl-formamide in a nitrogen atmosphere a solution of 0.1 mole ,,.,:~,', . ' . ' ~ ;;
: . , , . .~:
. .. .
.
WO91/1~57 PCT/NL91/00008;
20~4180 ~
thioureum, respectively thioformamide, respectively-an alkyl-thioamide in circa 50 ml of dry dimethylformamide is added with stirring. After the light exothermal reaction heating takes place at 100C for 3 hours. After cooling the . I
reaction mixture is high vacuum concentrated. Subsequently a little ethanol is added to the residue, it is stirred for 30 minutes, thereafter the crystalline material is fil-tered of r, washed with subsequently ethanol and diethylether, thereafter the precipitate ~ uacuumdried.If necessary it is re-10 crystallized from an appropriate solvent.
Thus there were obtained:
a. 2-amino-5-(2-Dhthalim ~ bromide (19a) _____ _____ _____ __ in 63% yield, from 2-bromo-4-phthalimido-1-butanol (18a) and thiour.ea.
The product was crystallized from an ethanol/methanol mixture.
Melting point 221-225C.
lH-NMR (D6-DMS0): 2.98 ppm., triplet tJ=6.8 Hz), 2H; 3.78 ppm., triplet (J,6.8 Hz), 2H; 7.10 ppm., singlet, lH;
20 7.86 ppm., singlet, 4H; 9.08 ppm., broad singlet, 2H.
., , ~ . . . , , ~ .
b 2-amino- ~ drobromide (19b) in 78.5% yield, from 2-bromo-5-phthalimido-1-pentanal (18b) and thioure~. -` H-NMR (D6-DMS0): 1.69-21.13 ppm., multiplet, 2H; 2.7Z ppm., 25 triplet (J=7.2 Hz), 2H; 3.66 ppm., triplet (J=6.3 Hz), 2H;
7.15 ppm., singlet, lH; 7.90 ppm.,singlet, 4H; 9.28 ppm., broad singlet, 2H.
. .
" ~ .
:` - - . -: : ' - . . . ~ -.: :: -- .' -: ~, : ' I WO91/1~57 PÇT/NL9l/~W~8 . ... ... .
S; !q ^~ ~
2074rs~b~ ~;
Example VI
____ .
H-NMR (CDCl3): 1.50-1.92 ppm., multiplet, 4H; 2.41-2.66 ppm., multiplet, 2H 3.73 ppm., triplet (J=6.8 Hz), 2H; 7.62-7.94 ppm., multiplet, 4H, 9.75 ppm., triplet (J=0.6 Hz), lH.
20 Exam~`le IV ` ~ -2-Bromo-~-phthalimido-1-alkanals (18) General process:
To a solution of 0.5 mole of an appropriate ~ -phthalimido-l-alkanol (17) in circa 500 ml of tetrachlorocarbon in a 25 nitrogen atmosphere stirring vigorously 80 g (0.5 mole) of bromine is cautiously added at room temperature. After decolor-ation of the reaction mixture stirring is continued at room temperature for 2 hours. Subsequently circa lO0 ml of ~`' .
.;
: ' , . . .
.
~ . .
~, i ': `
, ,. ~ .
~' ' ..
WO91/10657 PCT/NL91/~X~8 ~"~ } ~ i`'.J
13- 2~74180 chloroform and 500 ml of demineralized water are added, thereafter stirring takes place i~ a nitrogen atmosphere for 30 minutes. The water pha$e is removed and the organic phase is washed in a nitrogen atmosphere with demineralized~water to neutral reaction. After drying on anhydrous sodium sulfate and filtration the organic phase is vacuum concentrated. The viscous oil obtained is used without any purification for the preparation of the corresponding 5~ phthalimidoalkyl thiazoles (19).
10 Thus there were obtained:
a. 2-Bromo-4-phthalimido-1-butanal (18a) in 78.5 % yield, from 4-phthalimido-1-butanal (17a).
H-NMR (CDCl3: 2.00-2.75 ppm., multiplet, 2H; 3.87 ppm., triplet (J=6.8 Hz), 2H; 4.40 ppm, double triplet (J1=7.2 Hz, 15 J2= 1.8 Hz), lH; 7.59-7.96 ppm., multiplet, 4H; 9.45 ppm., doublet (J=1.8 Hz), lH.
b. 2-bromo-5-phthalimido-1-pentanal (18b) in 68% yield, __ from 5-phthalimido-1-pentanal (17b) H-NMR (CDCl3): 1.76-2.10 ppm.; multiplet, 4H; 3.73 ppm., 20 triplet (J=6.3 Hz), 2H; 4.36 ppm., broad triplet, lH; 7.60-7.92 ppm., multiplet, 4H; 9.40 ppm., doublet (J=1.8 Hz),lH.
-Example V
5-(~-phthalimidoalkyl)thiazoles (19) General process:
25 To a solution of 0.1 mole of an appropriate crude 2-bromo-phthalimido-1-alkanal (18) in circa 100 ml of dry dimethyl-formamide in a nitrogen atmosphere a solution of 0.1 mole ,,.,:~,', . ' . ' ~ ;;
: . , , . .~:
. .. .
.
WO91/1~57 PCT/NL91/00008;
20~4180 ~
thioureum, respectively thioformamide, respectively-an alkyl-thioamide in circa 50 ml of dry dimethylformamide is added with stirring. After the light exothermal reaction heating takes place at 100C for 3 hours. After cooling the . I
reaction mixture is high vacuum concentrated. Subsequently a little ethanol is added to the residue, it is stirred for 30 minutes, thereafter the crystalline material is fil-tered of r, washed with subsequently ethanol and diethylether, thereafter the precipitate ~ uacuumdried.If necessary it is re-10 crystallized from an appropriate solvent.
Thus there were obtained:
a. 2-amino-5-(2-Dhthalim ~ bromide (19a) _____ _____ _____ __ in 63% yield, from 2-bromo-4-phthalimido-1-butanol (18a) and thiour.ea.
The product was crystallized from an ethanol/methanol mixture.
Melting point 221-225C.
lH-NMR (D6-DMS0): 2.98 ppm., triplet tJ=6.8 Hz), 2H; 3.78 ppm., triplet (J,6.8 Hz), 2H; 7.10 ppm., singlet, lH;
20 7.86 ppm., singlet, 4H; 9.08 ppm., broad singlet, 2H.
., , ~ . . . , , ~ .
b 2-amino- ~ drobromide (19b) in 78.5% yield, from 2-bromo-5-phthalimido-1-pentanal (18b) and thioure~. -` H-NMR (D6-DMS0): 1.69-21.13 ppm., multiplet, 2H; 2.7Z ppm., 25 triplet (J=7.2 Hz), 2H; 3.66 ppm., triplet (J=6.3 Hz), 2H;
7.15 ppm., singlet, lH; 7.90 ppm.,singlet, 4H; 9.28 ppm., broad singlet, 2H.
. .
" ~ .
:` - - . -: : ' - . . . ~ -.: :: -- .' -: ~, : ' I WO91/1~57 PÇT/NL9l/~W~8 . ... ... .
S; !q ^~ ~
2074rs~b~ ~;
Example VI
____ .
6-bromo-2-hexanone t22a) ____ , . .
6-Bromo-2-hexanone (22a) is prepared according ~to a modified process as described in Dutch patent appiication 6511581 dated March 7,1966, cf. Chem. Abstr. 65, P20151d.
A mixture of 552 g (4 mole) of particulated anhydrous - potassium carbonate, 404 g (2 mole) of ~eshly distilled 1,3-dibromopropane, 260g (2 mole)offreshly distilled acetyl acetic ester and 700 ml of absolute ethanol is heated with vigorous stirring until circa 60C. After the mild exothermal reaction beginning at circa 50C, the reaction mixture is refluxed for circa 5 hours. After cooling the reaction mixture the inorganic salts are filtered off and the residue is rinsed with absolute ethanol. The combined filtrates are subsequently vacuum concentrated, thereafter to the residue circa 250 ml of demineralized water is added.
Subsequently it is extracted with toluene. The collectsd toluene phases are combined, dried on anhydrous sodium sulfate, filtered and subsequently vacuum conc.entrated.
Yield 73% on the basis of G.C./M.S. Subsequently 170.0 g i (1.00 mole) of the crude 2-methyl-3-carbethoxy-5,6-dihydro-pyrane together with 140 ml of concentrated aqueous HBr-solution (~8%) is refluxed with vigorous stirring for . . .
3 hours, and a violent evolution ~f carbondioxide gas takes place. After cooling the reaction mixture the formed 6-bromo-2-hexanone (22a) is extracted by means of chloroform, the collected chloroform phases are washed with demineralized water ., i, -. .
, ., ' ' :
.
: . .. .: , . . . ' :
~;'', ' - ' . " : "' :
:- , ::, . , , .- ,:
':. ' WO91/1~57 PCT/NL9l/~W~8 ` 2 0 7,~j8 Oy ,; - 16-to neutral reaction, thereafter dried on anhydrous sodium sulfate, filtered and vacuum concentrated. Subsequently the residue is subjected to fractionated distillation.- -Yield 104 g tO.58 mole) which corresponds with 79.4%.
~oiling point 102-106C/18 mm Hg. Reference:(Chem.Abst.., 65, P 2015id).
94-98C/12 mm Hg.
Mass spectrum M/Z (intensity in %). 180(0.14): 178(0.11);
137~6.3); 99 (100).
H-NMR (CDC13): 1.50-2.06 ppm., broad multiple , ~H; 2.14 ppm., single~, 3H; 2.48 ppm., triplet (J=6.3 Hz), 2H; 3.40 ppm., ~riplet (J=6.g Hz), 2H.
ExamDle VII
____ .
a. a-Dhthalimido-2-butanone (23a) 15 The 4-phthalimido-2-butanone (23a) was prepared according to a modified process by H.Irai et al., Kogyo Kagaku Zasschi, 62, pages 82-85 (1959) cf. Chem.Abstr., 58, 5659 b (1963) and such as described in Dutch patent application 8800998, April 18,1988.
; 20 Melting point 108.5-110C (Reference: H.Irai et al.,111-113C). -~
H-NMR (CDCl3): 2.22 ppm, singlet, 3H; 2.96 ppm., triplet (J=7.0 Hz), 2H; 3.96 ppm, triplet (J=7.0 Hz), 2H; 7.62-
6-Bromo-2-hexanone (22a) is prepared according ~to a modified process as described in Dutch patent appiication 6511581 dated March 7,1966, cf. Chem. Abstr. 65, P20151d.
A mixture of 552 g (4 mole) of particulated anhydrous - potassium carbonate, 404 g (2 mole) of ~eshly distilled 1,3-dibromopropane, 260g (2 mole)offreshly distilled acetyl acetic ester and 700 ml of absolute ethanol is heated with vigorous stirring until circa 60C. After the mild exothermal reaction beginning at circa 50C, the reaction mixture is refluxed for circa 5 hours. After cooling the reaction mixture the inorganic salts are filtered off and the residue is rinsed with absolute ethanol. The combined filtrates are subsequently vacuum concentrated, thereafter to the residue circa 250 ml of demineralized water is added.
Subsequently it is extracted with toluene. The collectsd toluene phases are combined, dried on anhydrous sodium sulfate, filtered and subsequently vacuum conc.entrated.
Yield 73% on the basis of G.C./M.S. Subsequently 170.0 g i (1.00 mole) of the crude 2-methyl-3-carbethoxy-5,6-dihydro-pyrane together with 140 ml of concentrated aqueous HBr-solution (~8%) is refluxed with vigorous stirring for . . .
3 hours, and a violent evolution ~f carbondioxide gas takes place. After cooling the reaction mixture the formed 6-bromo-2-hexanone (22a) is extracted by means of chloroform, the collected chloroform phases are washed with demineralized water ., i, -. .
, ., ' ' :
.
: . .. .: , . . . ' :
~;'', ' - ' . " : "' :
:- , ::, . , , .- ,:
':. ' WO91/1~57 PCT/NL9l/~W~8 ` 2 0 7,~j8 Oy ,; - 16-to neutral reaction, thereafter dried on anhydrous sodium sulfate, filtered and vacuum concentrated. Subsequently the residue is subjected to fractionated distillation.- -Yield 104 g tO.58 mole) which corresponds with 79.4%.
~oiling point 102-106C/18 mm Hg. Reference:(Chem.Abst.., 65, P 2015id).
94-98C/12 mm Hg.
Mass spectrum M/Z (intensity in %). 180(0.14): 178(0.11);
137~6.3); 99 (100).
H-NMR (CDC13): 1.50-2.06 ppm., broad multiple , ~H; 2.14 ppm., single~, 3H; 2.48 ppm., triplet (J=6.3 Hz), 2H; 3.40 ppm., ~riplet (J=6.g Hz), 2H.
ExamDle VII
____ .
a. a-Dhthalimido-2-butanone (23a) 15 The 4-phthalimido-2-butanone (23a) was prepared according to a modified process by H.Irai et al., Kogyo Kagaku Zasschi, 62, pages 82-85 (1959) cf. Chem.Abstr., 58, 5659 b (1963) and such as described in Dutch patent application 8800998, April 18,1988.
; 20 Melting point 108.5-110C (Reference: H.Irai et al.,111-113C). -~
H-NMR (CDCl3): 2.22 ppm, singlet, 3H; 2.96 ppm., triplet (J=7.0 Hz), 2H; 3.96 ppm, triplet (J=7.0 Hz), 2H; 7.62-
7.96 ppm., multiplet, 4H.
b. S-phthalimido-2-pentanone (23b) 25 The 5-phthalimido-2-pentanone (23a) is prepared according to Dutch patent application 8800998, April 18,1988.
Yield 53%
.
.
... . , -. . . . . .
::
:: , , , :
: - ' ,' ~ ~ - . , ' ~ , ;
WO91/10657 PCT/NL9l/~X~8 ~ .
' - 2 ~ 7 4 1 8 0 Melting point 72-74C.
1H-NMR (CDCl3): 1.89-2.12 ppm., multiplet, 2H; 2.15 ppm., singlet, 3H; 2.51 ppm., triplet (J=7.2 Hz), 2H;
3.72 ppm., triplet (J=6.6 Hz), 2H; 7.67-7.9Z ppm., multiplet, 4H.
c. 6-phthalimido-2-hexanone (23c) __ _ ___ __ _ The 6-phthalimido-2-hexanone (23b) is prepared as described for the 5-phthalimido-2-pentanone (23a) in Dutch patent applioation 8800998, April 18,1988.
Yield 80%, viscous oil.
H=NMR (CDC13): 1.48-1.80 ppm., multiplet, 4H; 2.14 ppm., singlet, 3H; 2.52 ppm., triplet (J-6.8 Hz), 2H; 3.70 ppm., triplet (J=6.3 Hz), 2H+ 7.66-7.90 ppm., multiplet, 4H.
Example VIII
3-Bromo- ~ -phthalimido-2-alkanones (24) ____ _ . _ __ : .
General process:
To a solution of 0.5 mole of an appropriate ~-phthal-imido-2-alkanone (23) in circa 500 ml of tetrachlorocarbon is cautiously added,with vigorous stirring, 80 g (0.5 mole) bromine at room temperature. After decoloration of the reaction mixture the stirring is continued at room temperat-ure for circa 2 hours. Subsequently there is added circa 100 ml chloroform and 500 ml of demineralized water, there-after it is stirred for 30 minutes. The water phase is subsequently removed .nd the organic phase is washed with ,'' .' .
:.;
. . ~.
. . .
...... ....... . . .. ..
' '!:
~:,:~., , ' ' :` . :
j`. ~;"-'` ~ . ., -` ;''.' ' ' , ',: . '` . .' ` ~
~' :. ' , .. ' .
WO91/1~7 PCT/NL91/~W~8 2~7 4180 ~
- 18 ~
demineralized water until neutral reaction. The organic phase is subsequently dried on anhydrous sodium sulfate, filtered and vacuum concentrated. The residue (viscous oil) is used without any purification for the preparation of the 2-amino~-;4-methy-5-( ~ -phthalimidoalkyl)thiazoles (25).
Thus there were obtained:
a. 3-Bromo-5-phthalimido-2-pentanone (Z4a) _ yield 95%, from 5-phthalimido-2-pentanone (23b).
H-NMR (CDC13): 2.10-2.59 ppm., multiplet, 2H; 2.40 ppm., 10 singlet, 3H; 3.82 ppm., triplet (J=6.3 HZ), 2H; 4.34 ppm., triplet (J=7.5 H7), lH; 7.69 ppm., multiplet, 4H.
b. 3-Bromo-6-Dhthalimido-2-hexanone (24b) _____ ____ _~__ yield 93%,from 6-phthalimido-2-hexanone (23c).
H-NMR ~CDCl3): 1.74-Z.22 ppm, multiplet, 4H; 2.36 ppm., 15 singlet, 3H; 3.46-3.90 ppm., multiplet, 2H; 4.36 ppm., triplet, (J~7.2 Hz), lH, 7.60-7.95 ppm., multiplet, 4H.
Example IX
~ L-~L~LELl)-4-methylthiazoles (25) General process:
To a solution of 0.2 mole of a crude 3-bromo-~phthal-imido-2-alkanone (24) in circa 100 ml of anhydrous dimethyl-formamide a solution of 0.2 mole of thiourea respectively thioformamide, respectively an alkylthioamide in circa 100 ml of dry dimethylformamide is added with stirring. After ,: .
~' ' ;,~ .
, , , , ;
.. , . . . . . ~ ' : : .
.. : .. . ..
... .. , :
' . : ~ ' . : ~ ' WO 91/10657 ' PCr/NL9l/00008' .,'"~
''~Z7~ff~7~ ?l~8o the exothermal reaction the temperature may rise to circa 100C, there is heated at circa 100C for circa 3 hours.
After cooling the'reaction mixture is high vacuum concentrat-ed, thereafter to the residue an 'ethylacetate/methanol 5 mixture (1:1 v/v) is added. After stirring circa 3~ minutes the precipl~te obtained is filtered'off, washed subsequently with ethylacetate and diethyl ether, thereafter the precipitate is vacuum dried.
Thus were obtained:
10 a. 2-Amino-5-(2-Dhthalimidoethyl)-a-methylthiazole ____ _______ _______ ___ ~ _________ hydrobomide (25a) __ _____ yield 50%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioureum.
H-NMR (D6-DMS0): 1.98 ppm., singlet, 3H; 2.98 ppm., triplet 15 (J-6,5 Hz), 2H; 3.76 ppm., triplet ~J=6.5 Hz) 2H; 7.91 ppm., singlet, 4H; 9.06 ppm., broad singlet, 2H.
b. 2-amino-5-(3-phthalimi~=ylthiazole hydrobromide (2_b) Yield 51%, from 3-bromo-6-pnthalimido-2-hexanone (24b) 20 and thioureum.
H-NMR (D6-DMS0): 1.61-2.04 ppm., multiplet, 2H, 2.15 ppm., singlet, 3H; 2.70 ppm., triplet (J=8.1 Hz), 2H; 3.64 ppm., triplet (J=6.6 Hz), 2H; 7.88 ppm., singlet, 4H-, 9.23 ppm., broad singlet, 2H.
25 c. 5-(2-phthalimidoethyl)-~-methylthiazole hydrobromide (25c) yield 40%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioformamide.
~. .
:
.
, .. ~..................... . . . . .
.: i . , -.
: ' , ,, ' ~ '~ . . .
r '. , i : ' , ;
' ::' , ' : . ' .
.. , . ...
W09l/1~57 PCT/NL91/~X~8 - ;2~ 8~ . ~
z~
Mel~ing point 207.4-210.6DC.
H-NMR (D6-DMS0): 1.99 ppm., singlet, 3H; 2.96 ppm., triplet ~J=6.3 Hz), 2H; 3.76 ppm., triplet (J-6.3 Hz), 2H; 7.92 ppm., singlet, 4H; 9.23 ppm., broad singlet, 2H.
d. 5-(2-phthalimidoethyl)-2.4-dimeth~ iazole hydrobromide (25d) yield 50%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioacetamidë.
H-NMR (D6-DMS0): 2.13 ppm., singlet, 3H; 2.70 ppm., singlet, 10 3H; ~.15 ppm., triplet (J=6.3 Hz), 2H; 3.78 ppm., triplet (J=6.3 Hz9, wH; 7.84 ppm., singlet, 4H; 8.78 ppm., broad singlet, lH.
. . .
Example X
l-bromo-~ -phthalimido-2-alkanones (27) The 1-bromo-~-phthalimido-2-alkanones (27) are prepared according to Dutch patent application 8800998, April 18,19880 Thus there were obtained~
a. l-bromo-4-phthalimido-2 butanone (27a). Yield 60%.
Melting point 120-122C (reference: R.G. Jones et al 20 J.Amer.Chem.Soc., 72, pages 4S26-4529 (1950) 119-120C).
H-NMR (CDC13): 3.13 ppm., triplet (J=7.2 Hz), 2H; 3.92 ppmO, singlet, 2H; 4.04-ppm., triplet (J=7.2 Hz), 2H; 7.60-7.96 ppm., multiplet, 4H.
b. l-bromo-5-phthalimido-2-pentanone (27b).
, ~ ~
25 Yield 52%. Melting point 131-133.4C (Reference: S.Elz and W.Schunack, Z.Natur. Forsch., 42b, p. 238-242 (1987) 122-125~.
. .
.. .:
.
;
;.:.
.. .
.. . . . .. . . . .
, :. ., : ' , . . :
, ., .: . , .;
: . . : -.
, WO9l/1~57 PCT/NL91/0~8 ~''' 2 0 7 ~}`,810 J. Michalksky et al, Chem.Listy, 49, p. 1379-1384 (1955) cf.
Chem.Abstr., 50, 5681 d (1956) 139C).
1H-NMR (CDC13): 1.82-2.24 ppm., multiplet, 2H; 2.74 ppm., triplet (J=7.2 Hz), 2H; 3.74 ppm., triplet (J=7.2 Hz), 2H; 3.94 ppm., singlet, 2H; 7.64-7.88 ppm., multiplet, 4H.
Example XI
___ 4-((~-Dhthalimidoalkyl)thiazoles (28) ____ ____ __ _ The 4-(~-phthalimidoalkyl)thiazoles (28) are prepared as described for the 5-(C~-phthalimidoalkyl)thiazoles (25) in example IX.
Thus there were obtained:
a. 2-amino-4-(2-Dhthalimidoethyl)th-azole h~robromide (28a) ___ ___ _ _____ . _ __ Yield 95X, from 1-bromo-4-phthalimido-2-butanone (27a) and thioureum.
H-NMR (D6-DMS0): 2.95 ppm., triplet (J=5.9 Hz), 2H;
3.87 ppm., triplet (J=5.9 Hz), 2H; 6.57 ppm., singlet, lH;
7.86 ppm., singlet, 4H; 8.98 ppm., broad singlet, ZH.
b. 2-amtno-4-(3-phthalimidopropyl)thiazole hydrobromide(28b) Yield 80X,- from 1-bromo-5-phthalimido-2-pentanone (27b) and thioureum.
H-NMR (D6-DMS0): 1.7Z-2.13 ppm., multiplet, 2H; 2.60 ppm., triplet (J=7.2 Hz), 2H; 3.62 ppm.,triplet (J=6.3 Hz), 2H;
6.56 ppm., singlet, 4H; 9.12 ppm., broad singlet, 2H.
:
., .
,.~
:
. . . ~ . .
:~, . ~ ..
`: . . . .. '' ' - : .
. : :
WO91/10657 PCT/NL91/~08 Exam~le XII
a- or 5-(~-aminoalkyl)thiazoles (20 26, 29) General process:
A solution of O.l mole of an appropriate ~-phthalimido-5 alkylthiazole hydrobromide (25) in circa 400 ml of anhydrous methanol is refluxed with 0.2 mole of an 80%-aqueous hydra-zine-hydrate solution for 5 hours. After cooling in ice the crystallized phthalhydrazine is filtered aff and the clear filtrate is vacuum concentrated. Subsequently 105 ml of a lO l molar aqueous sodium hydroxide solution is added to the residue, thereafter there is high-vacuum concentrated at room temperature. The residue obtained is stirred with warm absolute ethanol, which is high-vacuum concentrated after filtration. After taking up the residue in absolute 15 ethanol there is acidified with a concentrated aqueous 37%- hydrochloric acid solution until circa pH = 2, thereafter the mixture is high-vacuum concentra~ed at room temperature and residual water are azeotropically removed by using toluene. To the residue obtained 20 acetone is subsequently added, thereafter the c-ystalline material is filtered off,rinsedwith acetone and diethylether, thereafter it is vacuum dried, If necessary there is recrystallized from an appropriate solvent.
Thus were obtained:
a- 2-amino-5~(2-ami Yield 70%, from 2-amino-5-(2-phthalimidoethyl)thiazole i hydrobromide (29a).
Crystallized from methanol. Melting point 226-230C.
. . . .
: .
' "' ~` '' ' ~ ' . ' ' , : ~
', . ':, ~:
~ ~ .
~ ~ 7 WO91/1~57 PCT/NL91/~W~8 f.
2.,,Q~'7,4,..1,~
H-NMR (D6-DMS0): 2.88-3.14 ppm, broad singlet, 4H; 7.20 ppm., singlet, lH; 8.29 ppm, broad singlet, 3H; 9.35 ppm., singlet, 2H.
Mass 3pectrum M/Z (intensity in %): 143 (19.3); 127(3.4);
114 (100).
M+= 143.054 (calculated for C5HgN3S: 143.052) b. 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (20b) __ _ ___. __ ____________._ __ Yield 83%, from 2-amino-5-(3-phthalimidopropyl)thiazole hydrobromide (19b).
Crystallized from an ethanol/methanol mixture.
- H-NMR (D -DMS0): 1.68-2.10 ppm, multiplet, 2H; 2.79 ppm, broad triplet, 4H; 7.20 ppm, singlet, lH; 8.20 ppm, broad singlet, 3H; 9.46 ppm, broad singlet, 2H.
Mass spectrum M/2 (intensity in %): 157.(13.3): 141 (53.6);
127(100); 113 (9.5).
; M = 157-0 63 (calculated for C6HllN3S: 157.067) c 2-amino-5-(Z-aminoethyl)-4-methylthiazole dihydrochloride (26a) Yield 82%, from 2-amino-5-(2-phthalimidoethyl)-4-methyl-20 thiazole hydrobromide (25a).
H-NM~ (D6-DMS0): 2.19 ppm., singlet, 3H; 2.82-3.07 ppm.
broad singlet, 4H; 8.34 ppm., broad singlet, 3H; 9.32 ppm., broad singlet, 2H.
" Mass spectrum M/Z (intensity in %): 157(5.0); 141(3.8~;
127(5.0); 114(8.3).
M = 157.065 (calculated for C6Hl1N3S: 157.067) ...
. ~. .
~ .
;``' .
, ' ' ;:
WO91/1~57 PCT/NL91/~W~8 ~' 2''0"7~4-I'g"d' d. 2-amino-5-(3-aminoDropyl)-4-methylthiazole dihydro-___ _________ ____ ____ __ ______ _ _ __ _ chloride (26b). Yield 90%, from 2-amino-5-(3-Phthalimido-propyl)-4-methylthiazole hydrobromide (25b).
H-NMR (D6-DMS0): 1.66-2.02 ppm., multiplet, 2H; 2.16 ppm., singlet, 3H; 2.57-3.03 ppm, multiplet, 4H; 8.15 ppm, broad singlet, 3H; 9.32 ppm., broad singlet, 2H.
Mass spectrum M/Z (intensity in %): 171(28.9); 154(75.1);
127(100);~1il5(9.7).
M ~ 171.080 (calculated for C7H13N3S: 171-083)-e. 2-am_no-4-(2- min ethvl)th_az le d_h~ rochloride (_9a) Yield 64%, from 2-amino-4-(2-phthalimidoethyl)thiazole hydrobromide (28a).
H-NMR (D6-DMS0): 2.96 ppm., triplet (J=6.3 Hz), 2H;
3.12 ppm., triplet (J=6.3 Hz), ZH; 6.72 ppm., singlet, 15 lH; 8.04 ppm., broad singlet, 3H; 9.28 ppm., broad singlet, 2H.
Mass spectrum M/Z (intensity in %): 143(4.4); 127(9.9);
li4(100).
M = 143.052 (calculated for C5HgN3S: 143.052).
20 f. 2-amino-4-(3-aminopropyl)thiazole dihydrochloride (29b) Yield 70X, from 2-amino-4-(3-phthalimidopropyl)thiazole hydrobromide (28b).
H-NMR (D6-DMS0): 1.70-2.10 ppm., multiplet, 2H; 2.43-2.96 ppm., multiplet, 4H; 6.58 ppm.,singlet, lH; 8.31 ppm., broad singlet, 3H; g.40 ppm., broad singlet, 2H.
' .
' ' '' ` '' ' ` : , ;
`:.,. , ' ' '.: :'` . . ' ' :'. '`'.. - ~ ~. `
W091/1~57 PCTtNL9l/~W~8 ~ 'D, i "" , '`''''-~2"'0~7~ O
Mass spectrum M/Z (intensity in %): 157 (24.2); 140(42.5);
127(8.6); 113~30.0).
M .- 157.067 (calculated for C6H11N3S: 157-067) q. 5 (2-aminoeth ~ -4-methylthiazole dih~ochloride (26c) Yield 65%, from 5-(2-phthalimidoethyl)-4-methylthiazole (25c) by mild hydrolysis with hydrochloric acid as described by J.W. Black et al. in U.S.patent specification 3 736 331 dated May 29,1973.
H-NMR (D_-DMS0): 2.42 ppm., singlet, 3H; 2.84-3.40 ppm., multiplet, 4H; 8.01-8.51 ppm., broad singlet, 3H;
b. S-phthalimido-2-pentanone (23b) 25 The 5-phthalimido-2-pentanone (23a) is prepared according to Dutch patent application 8800998, April 18,1988.
Yield 53%
.
.
... . , -. . . . . .
::
:: , , , :
: - ' ,' ~ ~ - . , ' ~ , ;
WO91/10657 PCT/NL9l/~X~8 ~ .
' - 2 ~ 7 4 1 8 0 Melting point 72-74C.
1H-NMR (CDCl3): 1.89-2.12 ppm., multiplet, 2H; 2.15 ppm., singlet, 3H; 2.51 ppm., triplet (J=7.2 Hz), 2H;
3.72 ppm., triplet (J=6.6 Hz), 2H; 7.67-7.9Z ppm., multiplet, 4H.
c. 6-phthalimido-2-hexanone (23c) __ _ ___ __ _ The 6-phthalimido-2-hexanone (23b) is prepared as described for the 5-phthalimido-2-pentanone (23a) in Dutch patent applioation 8800998, April 18,1988.
Yield 80%, viscous oil.
H=NMR (CDC13): 1.48-1.80 ppm., multiplet, 4H; 2.14 ppm., singlet, 3H; 2.52 ppm., triplet (J-6.8 Hz), 2H; 3.70 ppm., triplet (J=6.3 Hz), 2H+ 7.66-7.90 ppm., multiplet, 4H.
Example VIII
3-Bromo- ~ -phthalimido-2-alkanones (24) ____ _ . _ __ : .
General process:
To a solution of 0.5 mole of an appropriate ~-phthal-imido-2-alkanone (23) in circa 500 ml of tetrachlorocarbon is cautiously added,with vigorous stirring, 80 g (0.5 mole) bromine at room temperature. After decoloration of the reaction mixture the stirring is continued at room temperat-ure for circa 2 hours. Subsequently there is added circa 100 ml chloroform and 500 ml of demineralized water, there-after it is stirred for 30 minutes. The water phase is subsequently removed .nd the organic phase is washed with ,'' .' .
:.;
. . ~.
. . .
...... ....... . . .. ..
' '!:
~:,:~., , ' ' :` . :
j`. ~;"-'` ~ . ., -` ;''.' ' ' , ',: . '` . .' ` ~
~' :. ' , .. ' .
WO91/1~7 PCT/NL91/~W~8 2~7 4180 ~
- 18 ~
demineralized water until neutral reaction. The organic phase is subsequently dried on anhydrous sodium sulfate, filtered and vacuum concentrated. The residue (viscous oil) is used without any purification for the preparation of the 2-amino~-;4-methy-5-( ~ -phthalimidoalkyl)thiazoles (25).
Thus there were obtained:
a. 3-Bromo-5-phthalimido-2-pentanone (Z4a) _ yield 95%, from 5-phthalimido-2-pentanone (23b).
H-NMR (CDC13): 2.10-2.59 ppm., multiplet, 2H; 2.40 ppm., 10 singlet, 3H; 3.82 ppm., triplet (J=6.3 HZ), 2H; 4.34 ppm., triplet (J=7.5 H7), lH; 7.69 ppm., multiplet, 4H.
b. 3-Bromo-6-Dhthalimido-2-hexanone (24b) _____ ____ _~__ yield 93%,from 6-phthalimido-2-hexanone (23c).
H-NMR ~CDCl3): 1.74-Z.22 ppm, multiplet, 4H; 2.36 ppm., 15 singlet, 3H; 3.46-3.90 ppm., multiplet, 2H; 4.36 ppm., triplet, (J~7.2 Hz), lH, 7.60-7.95 ppm., multiplet, 4H.
Example IX
~ L-~L~LELl)-4-methylthiazoles (25) General process:
To a solution of 0.2 mole of a crude 3-bromo-~phthal-imido-2-alkanone (24) in circa 100 ml of anhydrous dimethyl-formamide a solution of 0.2 mole of thiourea respectively thioformamide, respectively an alkylthioamide in circa 100 ml of dry dimethylformamide is added with stirring. After ,: .
~' ' ;,~ .
, , , , ;
.. , . . . . . ~ ' : : .
.. : .. . ..
... .. , :
' . : ~ ' . : ~ ' WO 91/10657 ' PCr/NL9l/00008' .,'"~
''~Z7~ff~7~ ?l~8o the exothermal reaction the temperature may rise to circa 100C, there is heated at circa 100C for circa 3 hours.
After cooling the'reaction mixture is high vacuum concentrat-ed, thereafter to the residue an 'ethylacetate/methanol 5 mixture (1:1 v/v) is added. After stirring circa 3~ minutes the precipl~te obtained is filtered'off, washed subsequently with ethylacetate and diethyl ether, thereafter the precipitate is vacuum dried.
Thus were obtained:
10 a. 2-Amino-5-(2-Dhthalimidoethyl)-a-methylthiazole ____ _______ _______ ___ ~ _________ hydrobomide (25a) __ _____ yield 50%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioureum.
H-NMR (D6-DMS0): 1.98 ppm., singlet, 3H; 2.98 ppm., triplet 15 (J-6,5 Hz), 2H; 3.76 ppm., triplet ~J=6.5 Hz) 2H; 7.91 ppm., singlet, 4H; 9.06 ppm., broad singlet, 2H.
b. 2-amino-5-(3-phthalimi~=ylthiazole hydrobromide (2_b) Yield 51%, from 3-bromo-6-pnthalimido-2-hexanone (24b) 20 and thioureum.
H-NMR (D6-DMS0): 1.61-2.04 ppm., multiplet, 2H, 2.15 ppm., singlet, 3H; 2.70 ppm., triplet (J=8.1 Hz), 2H; 3.64 ppm., triplet (J=6.6 Hz), 2H; 7.88 ppm., singlet, 4H-, 9.23 ppm., broad singlet, 2H.
25 c. 5-(2-phthalimidoethyl)-~-methylthiazole hydrobromide (25c) yield 40%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioformamide.
~. .
:
.
, .. ~..................... . . . . .
.: i . , -.
: ' , ,, ' ~ '~ . . .
r '. , i : ' , ;
' ::' , ' : . ' .
.. , . ...
W09l/1~57 PCT/NL91/~X~8 - ;2~ 8~ . ~
z~
Mel~ing point 207.4-210.6DC.
H-NMR (D6-DMS0): 1.99 ppm., singlet, 3H; 2.96 ppm., triplet ~J=6.3 Hz), 2H; 3.76 ppm., triplet (J-6.3 Hz), 2H; 7.92 ppm., singlet, 4H; 9.23 ppm., broad singlet, 2H.
d. 5-(2-phthalimidoethyl)-2.4-dimeth~ iazole hydrobromide (25d) yield 50%, from 3-bromo-5-phthalimido-2-pentanone (24a) and thioacetamidë.
H-NMR (D6-DMS0): 2.13 ppm., singlet, 3H; 2.70 ppm., singlet, 10 3H; ~.15 ppm., triplet (J=6.3 Hz), 2H; 3.78 ppm., triplet (J=6.3 Hz9, wH; 7.84 ppm., singlet, 4H; 8.78 ppm., broad singlet, lH.
. . .
Example X
l-bromo-~ -phthalimido-2-alkanones (27) The 1-bromo-~-phthalimido-2-alkanones (27) are prepared according to Dutch patent application 8800998, April 18,19880 Thus there were obtained~
a. l-bromo-4-phthalimido-2 butanone (27a). Yield 60%.
Melting point 120-122C (reference: R.G. Jones et al 20 J.Amer.Chem.Soc., 72, pages 4S26-4529 (1950) 119-120C).
H-NMR (CDC13): 3.13 ppm., triplet (J=7.2 Hz), 2H; 3.92 ppmO, singlet, 2H; 4.04-ppm., triplet (J=7.2 Hz), 2H; 7.60-7.96 ppm., multiplet, 4H.
b. l-bromo-5-phthalimido-2-pentanone (27b).
, ~ ~
25 Yield 52%. Melting point 131-133.4C (Reference: S.Elz and W.Schunack, Z.Natur. Forsch., 42b, p. 238-242 (1987) 122-125~.
. .
.. .:
.
;
;.:.
.. .
.. . . . .. . . . .
, :. ., : ' , . . :
, ., .: . , .;
: . . : -.
, WO9l/1~57 PCT/NL91/0~8 ~''' 2 0 7 ~}`,810 J. Michalksky et al, Chem.Listy, 49, p. 1379-1384 (1955) cf.
Chem.Abstr., 50, 5681 d (1956) 139C).
1H-NMR (CDC13): 1.82-2.24 ppm., multiplet, 2H; 2.74 ppm., triplet (J=7.2 Hz), 2H; 3.74 ppm., triplet (J=7.2 Hz), 2H; 3.94 ppm., singlet, 2H; 7.64-7.88 ppm., multiplet, 4H.
Example XI
___ 4-((~-Dhthalimidoalkyl)thiazoles (28) ____ ____ __ _ The 4-(~-phthalimidoalkyl)thiazoles (28) are prepared as described for the 5-(C~-phthalimidoalkyl)thiazoles (25) in example IX.
Thus there were obtained:
a. 2-amino-4-(2-Dhthalimidoethyl)th-azole h~robromide (28a) ___ ___ _ _____ . _ __ Yield 95X, from 1-bromo-4-phthalimido-2-butanone (27a) and thioureum.
H-NMR (D6-DMS0): 2.95 ppm., triplet (J=5.9 Hz), 2H;
3.87 ppm., triplet (J=5.9 Hz), 2H; 6.57 ppm., singlet, lH;
7.86 ppm., singlet, 4H; 8.98 ppm., broad singlet, ZH.
b. 2-amtno-4-(3-phthalimidopropyl)thiazole hydrobromide(28b) Yield 80X,- from 1-bromo-5-phthalimido-2-pentanone (27b) and thioureum.
H-NMR (D6-DMS0): 1.7Z-2.13 ppm., multiplet, 2H; 2.60 ppm., triplet (J=7.2 Hz), 2H; 3.62 ppm.,triplet (J=6.3 Hz), 2H;
6.56 ppm., singlet, 4H; 9.12 ppm., broad singlet, 2H.
:
., .
,.~
:
. . . ~ . .
:~, . ~ ..
`: . . . .. '' ' - : .
. : :
WO91/10657 PCT/NL91/~08 Exam~le XII
a- or 5-(~-aminoalkyl)thiazoles (20 26, 29) General process:
A solution of O.l mole of an appropriate ~-phthalimido-5 alkylthiazole hydrobromide (25) in circa 400 ml of anhydrous methanol is refluxed with 0.2 mole of an 80%-aqueous hydra-zine-hydrate solution for 5 hours. After cooling in ice the crystallized phthalhydrazine is filtered aff and the clear filtrate is vacuum concentrated. Subsequently 105 ml of a lO l molar aqueous sodium hydroxide solution is added to the residue, thereafter there is high-vacuum concentrated at room temperature. The residue obtained is stirred with warm absolute ethanol, which is high-vacuum concentrated after filtration. After taking up the residue in absolute 15 ethanol there is acidified with a concentrated aqueous 37%- hydrochloric acid solution until circa pH = 2, thereafter the mixture is high-vacuum concentra~ed at room temperature and residual water are azeotropically removed by using toluene. To the residue obtained 20 acetone is subsequently added, thereafter the c-ystalline material is filtered off,rinsedwith acetone and diethylether, thereafter it is vacuum dried, If necessary there is recrystallized from an appropriate solvent.
Thus were obtained:
a- 2-amino-5~(2-ami Yield 70%, from 2-amino-5-(2-phthalimidoethyl)thiazole i hydrobromide (29a).
Crystallized from methanol. Melting point 226-230C.
. . . .
: .
' "' ~` '' ' ~ ' . ' ' , : ~
', . ':, ~:
~ ~ .
~ ~ 7 WO91/1~57 PCT/NL91/~W~8 f.
2.,,Q~'7,4,..1,~
H-NMR (D6-DMS0): 2.88-3.14 ppm, broad singlet, 4H; 7.20 ppm., singlet, lH; 8.29 ppm, broad singlet, 3H; 9.35 ppm., singlet, 2H.
Mass 3pectrum M/Z (intensity in %): 143 (19.3); 127(3.4);
114 (100).
M+= 143.054 (calculated for C5HgN3S: 143.052) b. 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (20b) __ _ ___. __ ____________._ __ Yield 83%, from 2-amino-5-(3-phthalimidopropyl)thiazole hydrobromide (19b).
Crystallized from an ethanol/methanol mixture.
- H-NMR (D -DMS0): 1.68-2.10 ppm, multiplet, 2H; 2.79 ppm, broad triplet, 4H; 7.20 ppm, singlet, lH; 8.20 ppm, broad singlet, 3H; 9.46 ppm, broad singlet, 2H.
Mass spectrum M/2 (intensity in %): 157.(13.3): 141 (53.6);
127(100); 113 (9.5).
; M = 157-0 63 (calculated for C6HllN3S: 157.067) c 2-amino-5-(Z-aminoethyl)-4-methylthiazole dihydrochloride (26a) Yield 82%, from 2-amino-5-(2-phthalimidoethyl)-4-methyl-20 thiazole hydrobromide (25a).
H-NM~ (D6-DMS0): 2.19 ppm., singlet, 3H; 2.82-3.07 ppm.
broad singlet, 4H; 8.34 ppm., broad singlet, 3H; 9.32 ppm., broad singlet, 2H.
" Mass spectrum M/Z (intensity in %): 157(5.0); 141(3.8~;
127(5.0); 114(8.3).
M = 157.065 (calculated for C6Hl1N3S: 157.067) ...
. ~. .
~ .
;``' .
, ' ' ;:
WO91/1~57 PCT/NL91/~W~8 ~' 2''0"7~4-I'g"d' d. 2-amino-5-(3-aminoDropyl)-4-methylthiazole dihydro-___ _________ ____ ____ __ ______ _ _ __ _ chloride (26b). Yield 90%, from 2-amino-5-(3-Phthalimido-propyl)-4-methylthiazole hydrobromide (25b).
H-NMR (D6-DMS0): 1.66-2.02 ppm., multiplet, 2H; 2.16 ppm., singlet, 3H; 2.57-3.03 ppm, multiplet, 4H; 8.15 ppm, broad singlet, 3H; 9.32 ppm., broad singlet, 2H.
Mass spectrum M/Z (intensity in %): 171(28.9); 154(75.1);
127(100);~1il5(9.7).
M ~ 171.080 (calculated for C7H13N3S: 171-083)-e. 2-am_no-4-(2- min ethvl)th_az le d_h~ rochloride (_9a) Yield 64%, from 2-amino-4-(2-phthalimidoethyl)thiazole hydrobromide (28a).
H-NMR (D6-DMS0): 2.96 ppm., triplet (J=6.3 Hz), 2H;
3.12 ppm., triplet (J=6.3 Hz), ZH; 6.72 ppm., singlet, 15 lH; 8.04 ppm., broad singlet, 3H; 9.28 ppm., broad singlet, 2H.
Mass spectrum M/Z (intensity in %): 143(4.4); 127(9.9);
li4(100).
M = 143.052 (calculated for C5HgN3S: 143.052).
20 f. 2-amino-4-(3-aminopropyl)thiazole dihydrochloride (29b) Yield 70X, from 2-amino-4-(3-phthalimidopropyl)thiazole hydrobromide (28b).
H-NMR (D6-DMS0): 1.70-2.10 ppm., multiplet, 2H; 2.43-2.96 ppm., multiplet, 4H; 6.58 ppm.,singlet, lH; 8.31 ppm., broad singlet, 3H; g.40 ppm., broad singlet, 2H.
' .
' ' '' ` '' ' ` : , ;
`:.,. , ' ' '.: :'` . . ' ' :'. '`'.. - ~ ~. `
W091/1~57 PCTtNL9l/~W~8 ~ 'D, i "" , '`''''-~2"'0~7~ O
Mass spectrum M/Z (intensity in %): 157 (24.2); 140(42.5);
127(8.6); 113~30.0).
M .- 157.067 (calculated for C6H11N3S: 157-067) q. 5 (2-aminoeth ~ -4-methylthiazole dih~ochloride (26c) Yield 65%, from 5-(2-phthalimidoethyl)-4-methylthiazole (25c) by mild hydrolysis with hydrochloric acid as described by J.W. Black et al. in U.S.patent specification 3 736 331 dated May 29,1973.
H-NMR (D_-DMS0): 2.42 ppm., singlet, 3H; 2.84-3.40 ppm., multiplet, 4H; 8.01-8.51 ppm., broad singlet, 3H;
8.93 ppm., singlet, lH; 9.55 ppm., singlet, lH.
Mass spectrum M/Z (intensity in %): 143(12.4); 126(6.8);
113(32.9).
M = 142.054 (calculated for C6H1oN2S: 142.056) ; 15 h. 5_(2-aminoethyl)-2_4-dimethylthiazole dihydrochloride (26d) Yield 98%, from 5-(2-phthalimidoethyl)-2,4-____ dimethylthiazole (25d).
Melting point 159.5-163.35. -H-NMR (D6-DMS0): 2.41 ppm., singlet, 3H; 2.86 ppm., singlet, 3H; 2.94-3.33 ppm., multiplet, 4H; 8.47 ppm., ~ broad singlet, 3H. .--~ Mass spectrum M/Z (intensity in %): 156(2.1): 127(100);
85(3.8).
Example XIII
~` 25 5-(2-aminoethyl)_4-methylthiazole dihydrochloride (26c) The 5-(2-(aminoethyl)-4-methylthiazoledihydro-chloride (26c) may, if desired, also obtained in the following manner:
.
, ..
W091/10657 PCT/NL91/~H~8' , . ~tO ~ 8 ~ ~ !
A solution of 25.0 g (o.175 mole) of 5-(2-hydroxyethyl)-4-methylthiazole (Fluka A.G., Chem.Fabrik,CH-9470 Buchs) in 150 ml of aqueous 48% hydrogenbromidesolution is refluxed for 48 hours. After cooling the reaction mixture is vacuum concentrated and the residual water is removed azeotropically with toluene. Subsequently to the residue circa 50 ml o'f ethylacetate and 25 ml of absolute ethan are added and stirred for 30 minutes at room temperature.
The obtained precipitate is subsequently filtered off and 10 vacuum dried.
Yield 64% 5-(2-bromomethyl)-4-methylthiazole hydrobromide.
H-NMR (D6-DMS0): 2.46 ppm., singlet, 3H; 3.00 ppm., triplet (J=5.4 Hz), 2H; 3.65 ppm., triplet (J=5.4 Hz), 2H; 9.95 ppm., singlet, lH.
15A solution of 17.0 g (0.06 mole) of 5-(2-bromo-ethyl)-4-methylthiazole hydrobromide in circa lS0 ml of absolute ethanol is saturated with ammoniak gas at 0C, ,~
thereafter the mixture is heated in an autoclave at circa 100C for 16 hours. After cooling the-reaction mixture -is vacuum concentrated and the residue is taken up in deminer-alized water, then 11.76 g (0.14 mole) of sodium-hydrogen carbonate is added thereto, subsequently there is stirred at room temperature for circa one hour. After filtering the filtrate is vacuum concentrated and the ' 25 residual water is removed azeotropically by absolute ethanol. The residue is subsequently treated with warm methanol, the organic,salts are filtered off andthe filtrate , is brought at pH = 1 by using a concentrated hydrochloric acid solution. After vacuum concentration the residue is .
.
WO91/10657 PCT/NL91/~W~8 ¦ ' . . .
2 0 7 ~ ~}~ 0 .; ! . ~ !
- 27 _ subsequently crystallized from an ethanol/methanol mixture..
Yield 20%. Melting point 209-210C.
The lH-NMR~spectrum is identical to the spectrum as obtained with the preparation of the 5-(2-aminoethyl)-4-methylthiazole- ¦
dihydrochlorlde (26c) as described in example XIIg.
Example XIV
a. N-[3-(2-amino-a-~eth~lthiazole-5-yl)propyl] N'-cyano-0-phenylisoureum (32a) __ , ~o a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-aminopropyl)-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 ml of absolute ethanol is added with stirring. After heating at cir-ca 50C for 15 min., the inorganic material is filtered off lS and the filtrate is vacuum concentrated. The residue is subsequently taken up in 50 ml of dry freshly distilled pyridine, then 5.76 g (0.02 mole) of diphenyl cyanocarbon-imidate (31a) is added thereto.'After'' reflux''`f'or~2'hours, after cooling the reaction mixture is vacuum concentrated, ' 20 thereafter the residue is washed a few times with dry diethylether. The crystalline material is subsequently vacuum dried.
Yield lOOX.
H-NMR (CDC13): 1.65-2.04 ppm., multiplet, 2H; 2.63 ppm., ' 25 triplet (J=7.2 Hz), 2H; 3.41 ppm., triplet (J=6.3 Hz), 2H;
5.30 ppm., broad singlet, 2H; 7.00-7.19 ppm., multiplet, 2H;
7.19-7.53 ppm., multiplet, 3H.
: .
.
:' :~ . - .
.' , .
WO91t1~57 PCT/NL91/~W~8 07 ~ o~
b. N-[3-(2-aminothiazole-5-~l)prop~]-N'-cyano-S-methyliso-.__ _________ __ _ _ ____ ___ thioureum (32b) _______ _ To a solution of 4.60 g (0.02 mole) of 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (20b) in circa 50 ml 5 of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 mol of absolute ethanol is added ~ith stirring. After heating at circa 50C for 15 minutes the inorganic material is filtered offand 2.92 g (0.02 mole) of bis~methylthio]cyanocarbodiimide (31b) is added thereto, subsequently there is refluxed for 12 hours.
After cooling the reaction mixture is filtered and the -~
filtrate is vacuum concen~rated.
Yield 95%.
H-NMR (CDC13): 1.54-2.04 ppm., multiplet, 2H; 2.58 ppm., singlet, 3H; 2.68 ppm., triplet (J=5.4 Hz), 2H; 3.30 ppm., triplet (J=7.2 Hz), 2H, 6.63 ppm., singlet, lH; 6.70 ppm., singlet, 2H; 8.36 ppm., broad singlet, lH.
c. N-[3-(2-amino-4-mëthylthiazole-5-yl)propyl]-N'-cyano-S=
meth~lisothioureum (32c).
___ To a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-aminopropyl?-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 ml of absolute ethanol is added with stirring. After heating at circa 50C for 15 min., the inorganic material is filt-ered off and the filtrate is vacuum concentrated. Subsequently the .~ .
:
.
~ - . . , . . : .
.: . . ` , , : , :
, ; ': . . ..
.
:': ~: ' , , , '`' " ' :~
: ' '-,." , ., ,,,~,,,,, , ", ,~ " ;, ~ ",;;
.. : j . .
WO9l/1~7 - PCT/NL9l/~08-~
~07~41~80 the residue is taken up in 100 ml of dry freshly distilled pyridins, thereto 2.92 g (0.02 mole) of bis[methylthio]-cyanocarbodiimide (31b) is added. After reflux for 2 hours, the reaction mixture is vacuum concentrated and the residual pyridine is removed by codistillation with toluene. The residue is subsequently recrystallized from ethanol.
Yield: 85% melting point 172.0-172.4C.
H-NMR (D6-DMS0): 1.50-1.94 ppm., multiplet, 2H; 2.36-2.75 ppm. (under DMS0-signal), 2H; 2.60 ppm., singlet, 3H;
3.33 ppm., triplet (J=7.2 Hz), 2H; 6.65 ppm., singlet, 2H;
8.40 ppm., singlet, lH.
ExamDle XV
a. N-[3-(2-amino-4-methylthiazole-5-yl)propyl]quanidine -- __ __ dihydrobromide (32b) To a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-amino-propyl)-4-methylthiazoledihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in;circa 25 ml of absolute ethanol is added with stirring. After heating at circa 50C for 15 min., the inorganic material is filtered off and 3.70 g (0.02 mole) of S-ethylisothiouroniumbromide is added, then there is refluxed for 6 hours. After cooling the reaction mixture isfiltered off anda~cidified with concentrated aqueous hydrogen bromide solution to circa pH = 1, subsequent-ly there is vacuum concentrated and the residue is recrystall-; ized from a mixture of isopropyl alcohol and methanol.
- Yield 85%.
,~' . . -. , : ~ : . . : :
WO 91/1~57 PCT/~L91/~W~8 20~
H-NMR (D6-DMS0): 1.43-1.88 ppm., multiplet, 2H; 2.08 ppm., singlet, 3H; 2.20-2.72 ppm. ~partially under DMS0), multiplet, 2H; 2.83-3.29 ppm., multiplet, 2H; 7.32-7.88 ppm., broad singlet, 3H; 8.64 ppm., singlet, 4H; 9.10 ppm., singlet, 2H.
Example XVI `~ !
a. N-cyano-N'-(3.3-diphenyl~op ~ -0-phenylisoureum (36a) A solution of 10.55 g (0.05 mole) of 3,3-diphenyl-propylamine (33a) and ll.90 g (0.05 mole) of diphenylcyano- -carbonimidate (31a) in 100 ml dry dichloromethane is refluxed in nitrogen for 30 minutes. After cooling the react-ion mixture , it is vacuum concentrated, thereafter 100 ml of dry diethylether is added to the residue. Subsequently there is stirred in nitrogen at room temperature for 15 min-utes, thereafter the white crystalline material ïs filtered off,washed with dry diethyl ether and vacuum dried.
Yield 87%, melting point 171-174C.
H-NMR (D -DMS0): 2.}4-2.60 ppm.,multiplet, 2H; 3.00-3.A8 ppm., multiplet, 2H; 3.90-4.16 ppm., multiplet, lH;
7.00-7.65 ppm., multiplet, 15H; 8.73 ppm., broad singlet, lH.
b. N-cyano-N~-(3.3-di~ ylpropyl)-S-methylisothioureum (36b) .~
To a solution of 21.1 g (0.1 mole) of 3.3-diphenyl-propylamine (33a) in circa lOO`ml of dry diethylether a clear solution of 14.6 g (0.1 mole) of bis[methylthio]cyanocarbo-diimide (31b) in circa 100 ml of dry diethylether is added, - then there is stirred at room temperature for circa 30 min.
~he precipitate obtained is subsequently filtered off and washed :
,, , ~ , ., :
. ~ i .: .
, . : .: . .
;: . ~ .; . . ~ :: . .: -, :: ., . ., :
:- .. :
WO91/1~57 - PCT/NL91/~X~8 2 b'i~ 8 ~; f' ' .
with dry diethyl ether, thereafter the crystalline material is vacuum dried.
Yield 80%
H=NMR (CDCl3): 2.14-2.58 ppm., multiplet, 2H; 2.30 ppm., singlet, 3H; 3.16-3.50 ppm., multiplet, 2H; 3.95 ppm., triplet(J=8.1 Hz), lH; 7.26 ppm., multiplet, 10H; 7.58 ppm., broad singlet, lH.
Example XVII
a, N-benzo ~ ~ enylpropyl)thioureum (38a).
To a solution of 21.1 g (0.1 molej of 3,3-diphenyl-propylamine in 400 ml of dry diethyl ether in nitrogen atmosphere slowly and vigorously stirring a solution of 16.3 g (0.1 mole) of freshly distilled benzoylisothiocyanate (37) in circa 50 ml of dry diethyl ether is added, then it is stirred at room temperature for 1 hour. The precipitate obtained is filteredoff, washed with dry diethylether and ; vacuum dried.
- Yield 74%, melting point 124-125C.
- H-NMR (CDCl3): 3.26-3.54 ppm., multiplet, 2H; 4.40-4.70 ` 20 ppm., multiplet, 2H; 5.06 ppm., triplet (J=7.9 Hz), lH;
`i. 8.06-8.68 ppm., multiplet, 13H; 8.94 ppm., double doublet.
(J1=8.6 Hz, J2= 2.0 Hz), 2H; 11.95 ppm., broad singlet, lH.
.
:~"
~ : .
.
::.:. . . :. : .
,. ~ .
W091/1~57 PCT/NL9l/~H~8 ' 2 76 4 ~
b. N-(3,3-diphenylpropyl)thioureum (3ga) __________ _ _ _ To a solution of 26.2 g (0.07 mole) of N-benzoyl-N'-(3.3-diphenylpropyl)thioureum (38) in 500 ml of anhydrous methanol a saturated solution of 10.0 g (0.072 mole) of potassium!càrbonate in demineralized water is added, then it is rèfluxed with stirring for circa 6 hours. After cool-ing the formed precipitate is filtered off, washed with successively demineralized water and absolute methanol, then the precipitate is vacuum dried.
10 Yield 95%, melting point 198-199C.
H-NMR (D6-DMS0): 3.10-3.28 ppm., multiplet, 2H; 3.94-4.58 ppm., broad multiplet, 2H; 4.22 ppm., singlet, 2H; 5.03 ppm., triplet (J=7.7 Hz), lH; 8.02-8.60 ppm., multiplet, lOH; 8.83 ppm., singlet, lH.
c. S-ethyl-N-(3,3-diphenylpropyl)isothiouroniumbromide (40a) __ _ _ _ _ ____ _ A solution of 13.5 g (0.05 mole) of N-3,3-diphenyl-propyl)thioureum (39a) in circa 250 ml of absolute ethanol and 25 ml of bromomethane; is refluxed for 5 hours.
After cooling the solution is filtered and the filtrate is partially vacuum concentrated. The crystalline material is filteredoff,washed with dry diethyl ether and vacuum dried.
Yield 63%, melting point 176-180C.
-1H-NMR (D6-DMS0): 1.27 ppm., triplet (J=7.2 Hz), 3H; 2.16-2.53 ppm., multiplet, 2H; 3.08-3.40 ppm., multiplet, 4H; 4.06 ppm., triplet (J=7.7 Hz), lH; 7.07-7.46 ppm., multiplet, lOH; 9.13 ppm., broad singlet, lH; 9.56 ppm., triplet J=4.5 Hz), lH.
' .
` . ' : . '~' .
.:
,'' ' : ',., ''. ' :
.. . ,, , ~ ~
: ~ :
WO91/10657 PCT/NL911~W~8!
20~,4180~
Example XVIII
__ ____ a. N-[2-(Z-amino-4-methylthiazole-5-yl)ethyl] N~-(3.3-diphenylpro~ uanidine dipicrate (35a) To a solution of 2.3 g (0.01 mole) of 2-amino-5-(2-aminoethyl)-4-methylthiazole dihydrochloride (26a) in 50 ml of absolute ethanol a freshly prepared solution of 0.02 mole of sodium ethoxide in circa 25 ml of absolute ethanol is added. After stirring at circa 500C for 15 min.
it is cooled and the inorganic material is filtered off, then 3.55 g (O.Ol mole) of N-cyano-N'-(3,3-diphenylpropyl)-0-phenylisoureum (36a) is added thereto. Subsequently it is refluxed for 16 hours. After cooling and vacuum concentrat-ion the residue obtained is extracted a few times with dry diethylether. Subsequently circa 50 ml of heat ethylacetate is added, stirred for 15 minutes, the insoluble material is filtered off and the filtrate is vacuum concentrated. The viscous oil obtained, comprising crude N-[2-(2-amino-4-methylthiazole-5-yl)ethyl]-N~-cyano-N"-(3,3-diphenylpropyl)-~guanidine~(34a) is subsequently taken up without any purif-ication in 100 ml of 2N aqueous hydrochloric acid, there-after there is refluxed for 3 hours. After cooling there is vacuum concentrated and the residue dissolved in absolute methanol. After filtration a solution of 0.02 mole of picric acid in circa 50 ml of methanol is added. After stirring the precipitate obtained is filtered off andrecrystal-ized from a mixture of methanol and water.
Yield 10%.
"
'" ' '~
:, , - , , . .
W091/1~7 : PCT/NL91/~W~8 .~
't~
H-NMR (D6-DMSo): 2.12-2.46 ppm, broad multiplet, 2H;
2.70-3.53 ppm., broad multiplet, 6H; 4.02 ppm., i ' triplet (J=7.2 Hz), lH; 7.07-7.60 ppm.,'multipl'et,'' 13H;
8.64 ppm., singlet, 4H; 8.97 ppm., broad slnglet, 2H;
Mass spectrum M/Z (intensity in %): 143(12.4); 126(6.8);
113(32.9).
M = 142.054 (calculated for C6H1oN2S: 142.056) ; 15 h. 5_(2-aminoethyl)-2_4-dimethylthiazole dihydrochloride (26d) Yield 98%, from 5-(2-phthalimidoethyl)-2,4-____ dimethylthiazole (25d).
Melting point 159.5-163.35. -H-NMR (D6-DMS0): 2.41 ppm., singlet, 3H; 2.86 ppm., singlet, 3H; 2.94-3.33 ppm., multiplet, 4H; 8.47 ppm., ~ broad singlet, 3H. .--~ Mass spectrum M/Z (intensity in %): 156(2.1): 127(100);
85(3.8).
Example XIII
~` 25 5-(2-aminoethyl)_4-methylthiazole dihydrochloride (26c) The 5-(2-(aminoethyl)-4-methylthiazoledihydro-chloride (26c) may, if desired, also obtained in the following manner:
.
, ..
W091/10657 PCT/NL91/~H~8' , . ~tO ~ 8 ~ ~ !
A solution of 25.0 g (o.175 mole) of 5-(2-hydroxyethyl)-4-methylthiazole (Fluka A.G., Chem.Fabrik,CH-9470 Buchs) in 150 ml of aqueous 48% hydrogenbromidesolution is refluxed for 48 hours. After cooling the reaction mixture is vacuum concentrated and the residual water is removed azeotropically with toluene. Subsequently to the residue circa 50 ml o'f ethylacetate and 25 ml of absolute ethan are added and stirred for 30 minutes at room temperature.
The obtained precipitate is subsequently filtered off and 10 vacuum dried.
Yield 64% 5-(2-bromomethyl)-4-methylthiazole hydrobromide.
H-NMR (D6-DMS0): 2.46 ppm., singlet, 3H; 3.00 ppm., triplet (J=5.4 Hz), 2H; 3.65 ppm., triplet (J=5.4 Hz), 2H; 9.95 ppm., singlet, lH.
15A solution of 17.0 g (0.06 mole) of 5-(2-bromo-ethyl)-4-methylthiazole hydrobromide in circa lS0 ml of absolute ethanol is saturated with ammoniak gas at 0C, ,~
thereafter the mixture is heated in an autoclave at circa 100C for 16 hours. After cooling the-reaction mixture -is vacuum concentrated and the residue is taken up in deminer-alized water, then 11.76 g (0.14 mole) of sodium-hydrogen carbonate is added thereto, subsequently there is stirred at room temperature for circa one hour. After filtering the filtrate is vacuum concentrated and the ' 25 residual water is removed azeotropically by absolute ethanol. The residue is subsequently treated with warm methanol, the organic,salts are filtered off andthe filtrate , is brought at pH = 1 by using a concentrated hydrochloric acid solution. After vacuum concentration the residue is .
.
WO91/10657 PCT/NL91/~W~8 ¦ ' . . .
2 0 7 ~ ~}~ 0 .; ! . ~ !
- 27 _ subsequently crystallized from an ethanol/methanol mixture..
Yield 20%. Melting point 209-210C.
The lH-NMR~spectrum is identical to the spectrum as obtained with the preparation of the 5-(2-aminoethyl)-4-methylthiazole- ¦
dihydrochlorlde (26c) as described in example XIIg.
Example XIV
a. N-[3-(2-amino-a-~eth~lthiazole-5-yl)propyl] N'-cyano-0-phenylisoureum (32a) __ , ~o a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-aminopropyl)-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 ml of absolute ethanol is added with stirring. After heating at cir-ca 50C for 15 min., the inorganic material is filtered off lS and the filtrate is vacuum concentrated. The residue is subsequently taken up in 50 ml of dry freshly distilled pyridine, then 5.76 g (0.02 mole) of diphenyl cyanocarbon-imidate (31a) is added thereto.'After'' reflux''`f'or~2'hours, after cooling the reaction mixture is vacuum concentrated, ' 20 thereafter the residue is washed a few times with dry diethylether. The crystalline material is subsequently vacuum dried.
Yield lOOX.
H-NMR (CDC13): 1.65-2.04 ppm., multiplet, 2H; 2.63 ppm., ' 25 triplet (J=7.2 Hz), 2H; 3.41 ppm., triplet (J=6.3 Hz), 2H;
5.30 ppm., broad singlet, 2H; 7.00-7.19 ppm., multiplet, 2H;
7.19-7.53 ppm., multiplet, 3H.
: .
.
:' :~ . - .
.' , .
WO91t1~57 PCT/NL91/~W~8 07 ~ o~
b. N-[3-(2-aminothiazole-5-~l)prop~]-N'-cyano-S-methyliso-.__ _________ __ _ _ ____ ___ thioureum (32b) _______ _ To a solution of 4.60 g (0.02 mole) of 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (20b) in circa 50 ml 5 of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 mol of absolute ethanol is added ~ith stirring. After heating at circa 50C for 15 minutes the inorganic material is filtered offand 2.92 g (0.02 mole) of bis~methylthio]cyanocarbodiimide (31b) is added thereto, subsequently there is refluxed for 12 hours.
After cooling the reaction mixture is filtered and the -~
filtrate is vacuum concen~rated.
Yield 95%.
H-NMR (CDC13): 1.54-2.04 ppm., multiplet, 2H; 2.58 ppm., singlet, 3H; 2.68 ppm., triplet (J=5.4 Hz), 2H; 3.30 ppm., triplet (J=7.2 Hz), 2H, 6.63 ppm., singlet, lH; 6.70 ppm., singlet, 2H; 8.36 ppm., broad singlet, lH.
c. N-[3-(2-amino-4-mëthylthiazole-5-yl)propyl]-N'-cyano-S=
meth~lisothioureum (32c).
___ To a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-aminopropyl?-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in circa 25 ml of absolute ethanol is added with stirring. After heating at circa 50C for 15 min., the inorganic material is filt-ered off and the filtrate is vacuum concentrated. Subsequently the .~ .
:
.
~ - . . , . . : .
.: . . ` , , : , :
, ; ': . . ..
.
:': ~: ' , , , '`' " ' :~
: ' '-,." , ., ,,,~,,,,, , ", ,~ " ;, ~ ",;;
.. : j . .
WO9l/1~7 - PCT/NL9l/~08-~
~07~41~80 the residue is taken up in 100 ml of dry freshly distilled pyridins, thereto 2.92 g (0.02 mole) of bis[methylthio]-cyanocarbodiimide (31b) is added. After reflux for 2 hours, the reaction mixture is vacuum concentrated and the residual pyridine is removed by codistillation with toluene. The residue is subsequently recrystallized from ethanol.
Yield: 85% melting point 172.0-172.4C.
H-NMR (D6-DMS0): 1.50-1.94 ppm., multiplet, 2H; 2.36-2.75 ppm. (under DMS0-signal), 2H; 2.60 ppm., singlet, 3H;
3.33 ppm., triplet (J=7.2 Hz), 2H; 6.65 ppm., singlet, 2H;
8.40 ppm., singlet, lH.
ExamDle XV
a. N-[3-(2-amino-4-methylthiazole-5-yl)propyl]quanidine -- __ __ dihydrobromide (32b) To a solution of 4.88 g (0.02 mole) of 2-amino-5-(3-amino-propyl)-4-methylthiazoledihydrochloride (26b) in circa 50 ml of absolute ethanol 0.04 mole of a freshly prepared sodium ethoxide solution in;circa 25 ml of absolute ethanol is added with stirring. After heating at circa 50C for 15 min., the inorganic material is filtered off and 3.70 g (0.02 mole) of S-ethylisothiouroniumbromide is added, then there is refluxed for 6 hours. After cooling the reaction mixture isfiltered off anda~cidified with concentrated aqueous hydrogen bromide solution to circa pH = 1, subsequent-ly there is vacuum concentrated and the residue is recrystall-; ized from a mixture of isopropyl alcohol and methanol.
- Yield 85%.
,~' . . -. , : ~ : . . : :
WO 91/1~57 PCT/~L91/~W~8 20~
H-NMR (D6-DMS0): 1.43-1.88 ppm., multiplet, 2H; 2.08 ppm., singlet, 3H; 2.20-2.72 ppm. ~partially under DMS0), multiplet, 2H; 2.83-3.29 ppm., multiplet, 2H; 7.32-7.88 ppm., broad singlet, 3H; 8.64 ppm., singlet, 4H; 9.10 ppm., singlet, 2H.
Example XVI `~ !
a. N-cyano-N'-(3.3-diphenyl~op ~ -0-phenylisoureum (36a) A solution of 10.55 g (0.05 mole) of 3,3-diphenyl-propylamine (33a) and ll.90 g (0.05 mole) of diphenylcyano- -carbonimidate (31a) in 100 ml dry dichloromethane is refluxed in nitrogen for 30 minutes. After cooling the react-ion mixture , it is vacuum concentrated, thereafter 100 ml of dry diethylether is added to the residue. Subsequently there is stirred in nitrogen at room temperature for 15 min-utes, thereafter the white crystalline material ïs filtered off,washed with dry diethyl ether and vacuum dried.
Yield 87%, melting point 171-174C.
H-NMR (D -DMS0): 2.}4-2.60 ppm.,multiplet, 2H; 3.00-3.A8 ppm., multiplet, 2H; 3.90-4.16 ppm., multiplet, lH;
7.00-7.65 ppm., multiplet, 15H; 8.73 ppm., broad singlet, lH.
b. N-cyano-N~-(3.3-di~ ylpropyl)-S-methylisothioureum (36b) .~
To a solution of 21.1 g (0.1 mole) of 3.3-diphenyl-propylamine (33a) in circa lOO`ml of dry diethylether a clear solution of 14.6 g (0.1 mole) of bis[methylthio]cyanocarbo-diimide (31b) in circa 100 ml of dry diethylether is added, - then there is stirred at room temperature for circa 30 min.
~he precipitate obtained is subsequently filtered off and washed :
,, , ~ , ., :
. ~ i .: .
, . : .: . .
;: . ~ .; . . ~ :: . .: -, :: ., . ., :
:- .. :
WO91/1~57 - PCT/NL91/~X~8 2 b'i~ 8 ~; f' ' .
with dry diethyl ether, thereafter the crystalline material is vacuum dried.
Yield 80%
H=NMR (CDCl3): 2.14-2.58 ppm., multiplet, 2H; 2.30 ppm., singlet, 3H; 3.16-3.50 ppm., multiplet, 2H; 3.95 ppm., triplet(J=8.1 Hz), lH; 7.26 ppm., multiplet, 10H; 7.58 ppm., broad singlet, lH.
Example XVII
a, N-benzo ~ ~ enylpropyl)thioureum (38a).
To a solution of 21.1 g (0.1 molej of 3,3-diphenyl-propylamine in 400 ml of dry diethyl ether in nitrogen atmosphere slowly and vigorously stirring a solution of 16.3 g (0.1 mole) of freshly distilled benzoylisothiocyanate (37) in circa 50 ml of dry diethyl ether is added, then it is stirred at room temperature for 1 hour. The precipitate obtained is filteredoff, washed with dry diethylether and ; vacuum dried.
- Yield 74%, melting point 124-125C.
- H-NMR (CDCl3): 3.26-3.54 ppm., multiplet, 2H; 4.40-4.70 ` 20 ppm., multiplet, 2H; 5.06 ppm., triplet (J=7.9 Hz), lH;
`i. 8.06-8.68 ppm., multiplet, 13H; 8.94 ppm., double doublet.
(J1=8.6 Hz, J2= 2.0 Hz), 2H; 11.95 ppm., broad singlet, lH.
.
:~"
~ : .
.
::.:. . . :. : .
,. ~ .
W091/1~57 PCT/NL9l/~H~8 ' 2 76 4 ~
b. N-(3,3-diphenylpropyl)thioureum (3ga) __________ _ _ _ To a solution of 26.2 g (0.07 mole) of N-benzoyl-N'-(3.3-diphenylpropyl)thioureum (38) in 500 ml of anhydrous methanol a saturated solution of 10.0 g (0.072 mole) of potassium!càrbonate in demineralized water is added, then it is rèfluxed with stirring for circa 6 hours. After cool-ing the formed precipitate is filtered off, washed with successively demineralized water and absolute methanol, then the precipitate is vacuum dried.
10 Yield 95%, melting point 198-199C.
H-NMR (D6-DMS0): 3.10-3.28 ppm., multiplet, 2H; 3.94-4.58 ppm., broad multiplet, 2H; 4.22 ppm., singlet, 2H; 5.03 ppm., triplet (J=7.7 Hz), lH; 8.02-8.60 ppm., multiplet, lOH; 8.83 ppm., singlet, lH.
c. S-ethyl-N-(3,3-diphenylpropyl)isothiouroniumbromide (40a) __ _ _ _ _ ____ _ A solution of 13.5 g (0.05 mole) of N-3,3-diphenyl-propyl)thioureum (39a) in circa 250 ml of absolute ethanol and 25 ml of bromomethane; is refluxed for 5 hours.
After cooling the solution is filtered and the filtrate is partially vacuum concentrated. The crystalline material is filteredoff,washed with dry diethyl ether and vacuum dried.
Yield 63%, melting point 176-180C.
-1H-NMR (D6-DMS0): 1.27 ppm., triplet (J=7.2 Hz), 3H; 2.16-2.53 ppm., multiplet, 2H; 3.08-3.40 ppm., multiplet, 4H; 4.06 ppm., triplet (J=7.7 Hz), lH; 7.07-7.46 ppm., multiplet, lOH; 9.13 ppm., broad singlet, lH; 9.56 ppm., triplet J=4.5 Hz), lH.
' .
` . ' : . '~' .
.:
,'' ' : ',., ''. ' :
.. . ,, , ~ ~
: ~ :
WO91/10657 PCT/NL911~W~8!
20~,4180~
Example XVIII
__ ____ a. N-[2-(Z-amino-4-methylthiazole-5-yl)ethyl] N~-(3.3-diphenylpro~ uanidine dipicrate (35a) To a solution of 2.3 g (0.01 mole) of 2-amino-5-(2-aminoethyl)-4-methylthiazole dihydrochloride (26a) in 50 ml of absolute ethanol a freshly prepared solution of 0.02 mole of sodium ethoxide in circa 25 ml of absolute ethanol is added. After stirring at circa 500C for 15 min.
it is cooled and the inorganic material is filtered off, then 3.55 g (O.Ol mole) of N-cyano-N'-(3,3-diphenylpropyl)-0-phenylisoureum (36a) is added thereto. Subsequently it is refluxed for 16 hours. After cooling and vacuum concentrat-ion the residue obtained is extracted a few times with dry diethylether. Subsequently circa 50 ml of heat ethylacetate is added, stirred for 15 minutes, the insoluble material is filtered off and the filtrate is vacuum concentrated. The viscous oil obtained, comprising crude N-[2-(2-amino-4-methylthiazole-5-yl)ethyl]-N~-cyano-N"-(3,3-diphenylpropyl)-~guanidine~(34a) is subsequently taken up without any purif-ication in 100 ml of 2N aqueous hydrochloric acid, there-after there is refluxed for 3 hours. After cooling there is vacuum concentrated and the residue dissolved in absolute methanol. After filtration a solution of 0.02 mole of picric acid in circa 50 ml of methanol is added. After stirring the precipitate obtained is filtered off andrecrystal-ized from a mixture of methanol and water.
Yield 10%.
"
'" ' '~
:, , - , , . .
W091/1~7 : PCT/NL91/~W~8 .~
't~
H-NMR (D6-DMSo): 2.12-2.46 ppm, broad multiplet, 2H;
2.70-3.53 ppm., broad multiplet, 6H; 4.02 ppm., i ' triplet (J=7.2 Hz), lH; 7.07-7.60 ppm.,'multipl'et,'' 13H;
8.64 ppm., singlet, 4H; 8.97 ppm., broad slnglet, 2H;
9.06-9.74 ppm, broad singlet, lH.
b . N-~ 3-(2-amino-4-methylthia ~ ro~yl~-N ' -(3~3-di~henylpropyl)guanidine dipicrate (35b)_ _ __ ___ __ __ _ ____ The N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine (35b) was prepared in a manner analogous to that of the N-[2-(2-amino-4-methyl-thiazole-5-yl)ethyl]-N~-(3,3-diphenylpropyl)guanidine (35a), as described in example XVIIIa7 from N-cyano-N'-(3,3-diphenyipropyl)-0-phenylisoureum (37a) and 2-amino-5-(3-aminopropyl)-4-methylthiazole dihydrochloride (26b) with the proviso that the reaction mixture was refluxed for 48 hours.
Yield 45%
'1H_NM~ (D6-DMS0): 1.54-1.97 pFm., multiplet, 2H; 2.12 ppm., singlét, 3H;''2.22-2.50'ppm.~;'multiplet, 2H; 2.98-3.48-ppm., multiplet, 6H; 4.04 ppm., triplet, lH; 7.04-7.60 ppm., multiplet, 13H; 8.63 ppm., singlet, 4H; 9.12 ppm. broad singlet, 2H; 9.16-9.45 ppm., broad singlet, lH.
Example XIX -~
'' a. N-~3-(2-aminothiazole-5-yl)prop ~ 1-'~ 25 propyl)guanidine dipicrate (35c) To a solution of 2.30 g (0.01 mole) of 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (26b) in circa 50 ml :'.
~` ' ''`' ~`,;; .
:
:: :- .. ..
: . . . : . . ~ :
WO91/1~57 PCT/NL91/~W~8--207~180 of absolute ethanol, a freshly prepared solution of 0.02 m~e of sodiumethoxide in circa 25 ml of absolute.-ethanol is added. After stirring at 50C for 15 min. there is cooled ancl the inorganic material is filtered off, thereafter to the filtrate 3.79 g (0.01 mole) of S-ethyl-N-(3,3-diphenyl-propyl)isothiouronimbromide (40a) is added. After refluxing for 48 hours the reaction mixture is decolo~ised with activated carbon, filtered and the filtrate is vacuum concentrated.
The residue is taken up in circa 50 ml of methanol, then a solution of 0.02 mole of picric acid in 50 ml of methanol is added. After stirring for 2 hours the precipitate obtained is filtered OI~ and recrystallized from a mixture of methanoi and water.
Yield 30%
H-NMR (D6-DMS0): 1.56-1.98 ppm., multiplet, 2H; 2.00-2.80 ppm., multiplet, 4H; 2.90-3.34 ppm., multiplet, 4H; 4.01 ppm., triplet (J,7.2 Hz), lH; 7.13 ppm., singlet, lH;
7.31 ppm., broad singlet, 13H; 8.64 ppm., singlet, 4H;-9.12 ppm., broad singlet, 2H.
ExamDle XX
. _ . .
a. N-~3-(2-aminothiazole-4-yl)propyl]-N'-(3,3-diphenylpro guan~dine d ~
To a solution of 3.14 g (0.02 mole) of 2-amino-4-(3-aminopropyl)thiazole -(free base of 2-amino-4-(3-amino-propyl)thiazole dihydrochloride (29b) in circa 100 ml ofabsolute ethanol 6.18 g (0.02 mole) of N-cyano-N'-(3,3-diphenylpropyl)-S-methylisothioureum (36b) is added, .
`:
, ' : ' : , , .
, .
., :
WO 91/1~657 PCl/NL91/00008 20~ 80 n~L''it~v' then there is refluxed for 96 hours. After cooling the re;~ction mixture is decolorised with,activated carbon, filtered and vacuum concentrated. The residue is subsequently taken up in 100 ml of 2N aqueous hydrochloric acid 5 solution and refluxed for 4 hours. After cooling there is vacuum concentrated, thereafter the residue is taken up in circa lOO~m~l of absolute ethanol and the inorganic material is filtered of~ Tothe filtrate subsequently a solution of 0.04 mole of picri c acid in circa 50 ml of ethanol is
b . N-~ 3-(2-amino-4-methylthia ~ ro~yl~-N ' -(3~3-di~henylpropyl)guanidine dipicrate (35b)_ _ __ ___ __ __ _ ____ The N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine (35b) was prepared in a manner analogous to that of the N-[2-(2-amino-4-methyl-thiazole-5-yl)ethyl]-N~-(3,3-diphenylpropyl)guanidine (35a), as described in example XVIIIa7 from N-cyano-N'-(3,3-diphenyipropyl)-0-phenylisoureum (37a) and 2-amino-5-(3-aminopropyl)-4-methylthiazole dihydrochloride (26b) with the proviso that the reaction mixture was refluxed for 48 hours.
Yield 45%
'1H_NM~ (D6-DMS0): 1.54-1.97 pFm., multiplet, 2H; 2.12 ppm., singlét, 3H;''2.22-2.50'ppm.~;'multiplet, 2H; 2.98-3.48-ppm., multiplet, 6H; 4.04 ppm., triplet, lH; 7.04-7.60 ppm., multiplet, 13H; 8.63 ppm., singlet, 4H; 9.12 ppm. broad singlet, 2H; 9.16-9.45 ppm., broad singlet, lH.
Example XIX -~
'' a. N-~3-(2-aminothiazole-5-yl)prop ~ 1-'~ 25 propyl)guanidine dipicrate (35c) To a solution of 2.30 g (0.01 mole) of 2-amino-5-(3-aminopropyl)thiazole dihydrochloride (26b) in circa 50 ml :'.
~` ' ''`' ~`,;; .
:
:: :- .. ..
: . . . : . . ~ :
WO91/1~57 PCT/NL91/~W~8--207~180 of absolute ethanol, a freshly prepared solution of 0.02 m~e of sodiumethoxide in circa 25 ml of absolute.-ethanol is added. After stirring at 50C for 15 min. there is cooled ancl the inorganic material is filtered off, thereafter to the filtrate 3.79 g (0.01 mole) of S-ethyl-N-(3,3-diphenyl-propyl)isothiouronimbromide (40a) is added. After refluxing for 48 hours the reaction mixture is decolo~ised with activated carbon, filtered and the filtrate is vacuum concentrated.
The residue is taken up in circa 50 ml of methanol, then a solution of 0.02 mole of picric acid in 50 ml of methanol is added. After stirring for 2 hours the precipitate obtained is filtered OI~ and recrystallized from a mixture of methanoi and water.
Yield 30%
H-NMR (D6-DMS0): 1.56-1.98 ppm., multiplet, 2H; 2.00-2.80 ppm., multiplet, 4H; 2.90-3.34 ppm., multiplet, 4H; 4.01 ppm., triplet (J,7.2 Hz), lH; 7.13 ppm., singlet, lH;
7.31 ppm., broad singlet, 13H; 8.64 ppm., singlet, 4H;-9.12 ppm., broad singlet, 2H.
ExamDle XX
. _ . .
a. N-~3-(2-aminothiazole-4-yl)propyl]-N'-(3,3-diphenylpro guan~dine d ~
To a solution of 3.14 g (0.02 mole) of 2-amino-4-(3-aminopropyl)thiazole -(free base of 2-amino-4-(3-amino-propyl)thiazole dihydrochloride (29b) in circa 100 ml ofabsolute ethanol 6.18 g (0.02 mole) of N-cyano-N'-(3,3-diphenylpropyl)-S-methylisothioureum (36b) is added, .
`:
, ' : ' : , , .
, .
., :
WO 91/1~657 PCl/NL91/00008 20~ 80 n~L''it~v' then there is refluxed for 96 hours. After cooling the re;~ction mixture is decolorised with,activated carbon, filtered and vacuum concentrated. The residue is subsequently taken up in 100 ml of 2N aqueous hydrochloric acid 5 solution and refluxed for 4 hours. After cooling there is vacuum concentrated, thereafter the residue is taken up in circa lOO~m~l of absolute ethanol and the inorganic material is filtered of~ Tothe filtrate subsequently a solution of 0.04 mole of picri c acid in circa 50 ml of ethanol is
10 added. After stirring at room temperature for 3 h~urs, the precipitate obtained is filtered off and recrystallized from a mixture of methanoi and water.
Yield 30% D6DMS0.
H-NMR (D6DMS0): 1.54-1.95 ppm., multiplet, 2H; 2.09-2.74 ppm., multiplet, 4H; 2.87-3.30 ppm., multiplet, 4H; 3.98 ppm., triplet (J=7.2 Hz), lH; 6.50 ppm., singlet, lH; 7.16 ppm., broad singlet, 13H; 8.60 ppm., singlet, 4H; 8.96 ppm., broad singlet, 2H.
ExamDle XXI
__ _ 20 a. N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-di~he_ylpropyl)R9~:~
A solution of 3.05 g (0.01 mole) of N-[3-(2-amino-4.methyl~hiazole-5-yl)propyl]-N'-cyano-0-phenylisoureum (32a) and 4.22 g (0.02 mole) of 3,3-diphenylpropylamine (33a) in 25 circa 100 ml of freshly distilled anhydrous pyridine is refluxed for 16 hours. After cooling the reaction mixture is .
vacuum concentrated. The residue is subsequently washed with successively demineralized water and diethyl ether, there-after the residue is taken up in circa lO0 ml of hot ethyl-,.
' " ' : . " ' . ' , ': :, , . i ' : ' ' , ' :
. ~; . .. .. . . .
~ . . . .
.,.':' . '' :. ' -' . ~ - ~ ' WO91/1~57 PCT/NL91/~W~8 ~-,', ' t; ;~ 20~7~18o acetate.Af~er dec~oration with activated coal and filtration the filtrate is vacuum concentrated. The viscous oil obtained comprising N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-N"-(3,3-diphenylpropyl)guanidine (34b) is hydrolyzed 5 after column chromatography (Kieselgel 60-80, eluent methanol~NH3) by 2N aqueous hydrochloric acid solution and converted into the dipicrate as described for the N-[3-(2-aminothiazole-4-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine dipicrate (35d) in example XXa.
lO Yield 65%
~ -NMR (D6-DMS0): identical to the spectrum as described for the N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine dipricate (35b) in example XVIIIb.
ExamDle XXII
__ i5 a- N~Nl-bls[3-(2-amlno-4-methylthiazole_5_rl?proDrl]
~anidine dip crate (35e) To a solution of 2.44 g (o.Ol mole) of 2-amino-5-; (3-aminopropyl)-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol a solution of 0.02 mole of freshly prepared sodiumethoxide in 25 ml of absolute ethanol is added. After stirring at 50C for l5 minutes there is cooled and the inorganic material is filtered off, then the filtrate is vacuum concentrated. Subsequently the - residue is taken up in circa lO0 ml of freshly distilled anhydrous pyridine, thereto 2.69 g (O.Ol mole) of N-~3,2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothio-ureum (32c) is added, thereafter the mixture is refluxed for 12 hours. After cooling the reaction mixture is processed :
.~'; .
.
. . .: , , ,.~, , . . , ,, ' .
.
:, ' , :
~ :, ' . . :
WO91/10657 PCTtNL91/UN~8 ~ o~4~8~ 38 -as described for the N-[3-(2-amino-4-methylthiazole-5-yl)-propyl]-N'-(3,3-diphenylpropyl)-guanidine dipicrate (35b) as described in example XXIa.
Yield 50%
H-NMR (D6-DMS0): 1.43-1.88 ppm., multiplet, 4H; 2.08 ppm., singlet, 6H; 2-~20-2.72 ppm., (partially under DMS0), multiplet.,~ 4H, 2.83-3.29 ppm., multiplet, 4H; 7.32-7.38 ppm., broad singlet, 3H; 8.64 ppm., singlet, 6H: 9.10 ppm., singlet, 4H.
-- ~0 ExamDle XXIII
___ _ , N-[3-(2=amino-4_methylthiazole_5_yl)propyl]=N'-cyano_N~_ methylguanidine (34c) __ __ __ :
To a solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-3-methylisothioureum (32c) in circa 25 ml of absolute ethanol 5 8 Of methylamine in 50 ml of absolute ethanol is atded, thereafter with stirring for circa 5 hours there is refluxed. After cooling , the reaction mixture is vacuum concentrated, thereafter the residue is cryst'allized from absolute'~ethanol. - ~ -Yield 92%. Melting poi'nt 167.8-172C (decomposition) H=NMR'(D6-DMS0): 1.49-1.82 ppm., multiplet, 2H; 1.97 ppm., singlet, 3H; 2.32-2.50 ppm., multiplet, 2H; partially : under DMS0); 2.67 ppm., doublet (J= 5.0 Hz), 3H; 2.95-3.28 ppm., multiplet, 2H; 6.60 ppm., broad singlet, 2H; 6.84-7.10 ppm., multiplet, 2H.
: Example XXIV
N-[3-(2-amino-4-methylthiazole-5-yl)pr~ ]-N'-cyano-N"-[3-(4-morpholino)propyl]guanidine (34d) .' ' .
, . - :, ', : , : .
. . . .;.,. . ' : : ' ~ . : ~
.: ~ : : . ~ - : .
-: . , - ., . . . . -, . :
.: ' ~ ' - - :' - - ' , ~: . . . . . . .
WO91/1~57 PCT/NL91t~W~8:
f~''.
207~ 80 ~ `
To a solution of 1.34 g (0.005 mole) of N-E3-(2-amino-4-met;hylthiazole-5-yl)propyl]-N'-cyano-5-methyl isothioureum ~32c) in circa 50 ml of pyridine 1.44 g (0.01 mole) of 3-(4-morpholino)propylamine is added, then with stirring in a nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl-ether. Subsequently it is recrystallized from a mixture of absolute ethanol and methanol.
10 Yield 48%. Melting point 149.0-151.2C.
H-NMR (D6-DMS0); 1.70-1.90 ppm., multiplet,4H; 2.01 ppm., . singlet, 3H; 2.11-2.70 ppm., multiplet, 8H; 3.00-3.36 ppm., multiplet, 4H; 3.54-3.78 ppm., multiplet, 4H; 6.65 ppm., singlet, 2H; 7.12-7.46 ppm, multiplet, 2H.
Example XXV
__ N-~-3-(2-amlno-4-methylthlazole-5-yl~propyl] N'-c~ano=N"-(3-phenylbutyl)guanidine (34e) __ _ _ _ :. . .... .. . . . . .
To a solution of 1.34 g (0.005 mole) N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum (32c) in circa 50 ml of pyridine 1.499 (0.01 mole) of 4-phenylbutylamine is added, thereafter with stirring in a ; nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl - 25 ether. Subsequently it is recrystallized from absolute ethanol.
Yield 51~. Me1ting point 159.3-161.9C.
`'-;
;
.
.:
' ' ~
.
.
:. . . .
;
.
. :-. . .
WO91~ 7 PCTtNL91/~N~8 20~80~1 .
H-NMR (D6-DMS0): 1.30-1.35 ppm., multiplet, 6H; 1.98 ppm., singlet! 3H; 2.32-2.75 ppm., multiplet, 4H (partially under DMS0): 2.96-3.38 ppm, multiplet, 4H; 6.62 ppm., singlet, 2H; 6.97-7.18 ppm., multiplet, 2H; 7.26 ppm., singlet, 5H.
Example XXVI
N-[3-t2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-N"-__ __ _ _______ _____ __ (3,3-dlphenylpropy ~ uanidine (34f)_ To a solution of 1.34 g (0.005 mole) N-[3-(2-amino-a-methylthiazole-s-yl)propyl]-N~-cyano-s-methylisothioureum (32c) in circa 50 ml of pyridine 2.11 g (0.01 mole) of 3,3-diphenylpropylamine is added, then with stirring in a nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl-ether. Subsequently it is recrystallized ~rom absolute ethanol.
Yield 60% Melting point 164.7-168.8-C.
H-NMR (D -DMS0): 1.44-1.82 ppm., multiplet, 2H; 1.92 ppm., . 1 6 singlet, 3H; 2.14-2.50 ppm., multiplet, 2H (partially ; 20 under DMS0); 2.86-3.24 ppm., multiplet, 4H; 3.24-3.60 ppm., multiplet, 2H; 3.98 ppm., triplet (J=8.0 Hz), lH; 6.58 ppm., broad singlet, 2H; 6.86-7.25 ppm., multiplet, 12H.
Example XXVII
,. - - .-N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-~3-(3,4-dichlorophenyl)-3-(2-pyridyl)propyl]guanidine tripicrate(35f) ... ~, . . . . . ~ . , .
' . . . .. ~
'. .
.
, .
.
.:
WO 9l/10657 - PCl/NL91/00008 . ,:; .
- 41 - 2tO741~80 A solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yi)propyl]-NI-cyano-S-methylisothioureum (32c) and 1.41 g (0.005 mole) of 2-[3-amino-1-(3,4-dichloro-phenyl)propyl]pyridine~ in circa 50 ml of pyridine is 5 refluxed with stirring in a nitrogen atmosphere for 72 hours.
After cooling the reaction mixture is vacuum concentrated and the residue is washed a few times with diethyl ether.
Subsequently 25 ml of 6M hydrochloric acid solution is added thereto and there is refluxed for 6 hours. After cooling the 10 reaction mixture is vacuum concentrated and the residue is taken up in circa 25 ml of methanol, thereto 4.5 g of pitric acid in circa 50 ml of hot methanol is added.
Subsequently circa 5 ml of demineralized water is added and the precipitate obtained is filtered off, then 15 it is recrystallized from an ethanol/acetone mixture.
Yield 53%.
lH-NMR (D6-DMS0): 1.59-1.83 ppm., multiplet, 2H; 2.10 ppm., singlet, 3H; 2.30-2.71 ppm., multiplet, 4H; 3.00-3.39 ppm., multiplet, 4H; 4.42 ppm., triplet (J=6.7 Hz), lH; 7.20-8.97 ppm., multiplet, 9H; 8.10-8.31 ppm., multiplet, lH; 8.59 ppm., singlet, 6H; 8.65-8.80 ppm., multiplet, lH; 9.15 ppm., singlet, 2H.
Example XXVIII
N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3-phenyl propyl)guanidine dipicrate t35~
A solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum ~32c) and 1.35 g (0.01 mole) of 3-phenylpropylamino in circa 2-[3-amino-1-(3,4-dichlorophenyl)propyl]pyridine was obtained in a modif-ied process as described by A.Buschauer et al. Archiv.der Pharm.,322(3), 165-171 (1989) ~' "`; ~ ' . . : ' :'`;`' :
..
: ' ' - : .
WO9l/1~57 PCT/NL91/~W~8' j .
s l r ~ 4i80~ 42 -50 ml of pyridine with stirring in a nitrogen atmosphere for 72 hours there i.5 refluxed. After cooling the reaction mixture is vacuum concentrated and the residue' is washed a few times with diethylether. Subsequently 25 ml of 6M hydro-. .
chloric acid solution is added and there is refluxed for 6 hours. After coollng the reaction mixture is vacuum con- ;
centrated and the residue is taken up in circa 25 ml of methanol, then 3.05 g of picric acid in circa 50 ml of methanol is added thereto. Subsequently circa 5 ml of demineralized water is added thereto and the precipitate ob-- tained is filtered off,then recrystallized from a methanol/water mixture.
Yield 62%.
H-NMR (D6-DMS0): 1.53-2.20 ppm., multiplet, 4H; 2.07 ppm., ' 15 singlet, 3H; 2.40-2.78 ppm., multiplet, 4H (partially , under DMS0); 3.00-3.76 ppm., multiplet, 4H; 7.00-7.26 ppm., '~ multiplet, 8H; 8.6Z ppm., singlet, 4H; 9.14 ppm., singlet, 2H.
; ExampleXXIX
' 20 N-[3-(2-amino-a-methylthiazo propyl)guanidine dipicrate (35h) A solution of 1.34 g (0.005 mole) of N-~3-(2-amino-4-methyl-thiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum (32c) ' and 1.25 g (0.01 mole) of N-(3-aminopropyl)imidazole in circa 50 ml of pyridine is refluxed with stirring in a . , .
~'; nitrogen atmosphere for 72 hours. After cooling the reaction 'd mixture is vacuum concentrated and the residue is washed a ' few times wlth cold methanol. Subsequently 25 ml of 6M hydro-' ' . ., ~.
~,~ . . . .
~ - .
.~ .~: - , ' .~ , . ': '- . . ' : ... .
..
, WO91/1~57 PCTtNL9l/~H~8 2 0~7`~ ~ -8`~5l ~
_ 43 -chloric acid solution is added thereto and~there is refluxed for 6 hours. After cooling the reaction mixture is vacuum concentrated and the residue is taken up in circa 25 ml o f methanol, thereto 3.05 g of picric acid in circa 50 ml of methanol is added. Subsequently circa 5 ml of demineralized water is added thereto and the precipitate obtained is filtered off, then it is recrystallized from a methanol/water mixture.
Yield 38%.
H-NMR (D6-DMS0); 1.60-1.90 ppm., multiplet, 2H; 2.06 ppm., singlet, 3H; 2.06-2.34 ppm., multiplet, 2H; 2.54-2.98 ppm., multiplet, 4H; 3.14-3.60 ppm., multiplet, 2H; 4.28 ppm., triplet (J=7.2 Hz), 2H; 7.22-7.92 ppm., multiplet, 5H; 8.59 ppm., singlet, 4H; 9.10 ppm., singlet, 2H.
~ , .. . .. . . .
: ~
,: . - - .- :, . .
, ~ :" . . .. - :
WO 91t11K~;7 PCI`/NL91/OOOOf~.~
2 0 7 4 1 8 ~
... . .
Table I H2-activities on the g~ineQ-pig right atrium nr. C ompoun (J p D2 ( ~ 0,1 35d ~H H ~S S,9 35C ~J ~JH NH2 H H/'V~\N 6,4 ~ '.
~H H S
~) ~J H
35b ~ , ,C\ ~, 7,3 `` Cl \~
Cl NH2 ~\H H/~S =\~`l :.. ' NH2 histamine 6,1 .
. :
. ~
Yield 30% D6DMS0.
H-NMR (D6DMS0): 1.54-1.95 ppm., multiplet, 2H; 2.09-2.74 ppm., multiplet, 4H; 2.87-3.30 ppm., multiplet, 4H; 3.98 ppm., triplet (J=7.2 Hz), lH; 6.50 ppm., singlet, lH; 7.16 ppm., broad singlet, 13H; 8.60 ppm., singlet, 4H; 8.96 ppm., broad singlet, 2H.
ExamDle XXI
__ _ 20 a. N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-di~he_ylpropyl)R9~:~
A solution of 3.05 g (0.01 mole) of N-[3-(2-amino-4.methyl~hiazole-5-yl)propyl]-N'-cyano-0-phenylisoureum (32a) and 4.22 g (0.02 mole) of 3,3-diphenylpropylamine (33a) in 25 circa 100 ml of freshly distilled anhydrous pyridine is refluxed for 16 hours. After cooling the reaction mixture is .
vacuum concentrated. The residue is subsequently washed with successively demineralized water and diethyl ether, there-after the residue is taken up in circa lO0 ml of hot ethyl-,.
' " ' : . " ' . ' , ': :, , . i ' : ' ' , ' :
. ~; . .. .. . . .
~ . . . .
.,.':' . '' :. ' -' . ~ - ~ ' WO91/1~57 PCT/NL91/~W~8 ~-,', ' t; ;~ 20~7~18o acetate.Af~er dec~oration with activated coal and filtration the filtrate is vacuum concentrated. The viscous oil obtained comprising N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-N"-(3,3-diphenylpropyl)guanidine (34b) is hydrolyzed 5 after column chromatography (Kieselgel 60-80, eluent methanol~NH3) by 2N aqueous hydrochloric acid solution and converted into the dipicrate as described for the N-[3-(2-aminothiazole-4-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine dipicrate (35d) in example XXa.
lO Yield 65%
~ -NMR (D6-DMS0): identical to the spectrum as described for the N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3,3-diphenylpropyl)guanidine dipricate (35b) in example XVIIIb.
ExamDle XXII
__ i5 a- N~Nl-bls[3-(2-amlno-4-methylthiazole_5_rl?proDrl]
~anidine dip crate (35e) To a solution of 2.44 g (o.Ol mole) of 2-amino-5-; (3-aminopropyl)-4-methylthiazole dihydrochloride (26b) in circa 50 ml of absolute ethanol a solution of 0.02 mole of freshly prepared sodiumethoxide in 25 ml of absolute ethanol is added. After stirring at 50C for l5 minutes there is cooled and the inorganic material is filtered off, then the filtrate is vacuum concentrated. Subsequently the - residue is taken up in circa lO0 ml of freshly distilled anhydrous pyridine, thereto 2.69 g (O.Ol mole) of N-~3,2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothio-ureum (32c) is added, thereafter the mixture is refluxed for 12 hours. After cooling the reaction mixture is processed :
.~'; .
.
. . .: , , ,.~, , . . , ,, ' .
.
:, ' , :
~ :, ' . . :
WO91/10657 PCTtNL91/UN~8 ~ o~4~8~ 38 -as described for the N-[3-(2-amino-4-methylthiazole-5-yl)-propyl]-N'-(3,3-diphenylpropyl)-guanidine dipicrate (35b) as described in example XXIa.
Yield 50%
H-NMR (D6-DMS0): 1.43-1.88 ppm., multiplet, 4H; 2.08 ppm., singlet, 6H; 2-~20-2.72 ppm., (partially under DMS0), multiplet.,~ 4H, 2.83-3.29 ppm., multiplet, 4H; 7.32-7.38 ppm., broad singlet, 3H; 8.64 ppm., singlet, 6H: 9.10 ppm., singlet, 4H.
-- ~0 ExamDle XXIII
___ _ , N-[3-(2=amino-4_methylthiazole_5_yl)propyl]=N'-cyano_N~_ methylguanidine (34c) __ __ __ :
To a solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-3-methylisothioureum (32c) in circa 25 ml of absolute ethanol 5 8 Of methylamine in 50 ml of absolute ethanol is atded, thereafter with stirring for circa 5 hours there is refluxed. After cooling , the reaction mixture is vacuum concentrated, thereafter the residue is cryst'allized from absolute'~ethanol. - ~ -Yield 92%. Melting poi'nt 167.8-172C (decomposition) H=NMR'(D6-DMS0): 1.49-1.82 ppm., multiplet, 2H; 1.97 ppm., singlet, 3H; 2.32-2.50 ppm., multiplet, 2H; partially : under DMS0); 2.67 ppm., doublet (J= 5.0 Hz), 3H; 2.95-3.28 ppm., multiplet, 2H; 6.60 ppm., broad singlet, 2H; 6.84-7.10 ppm., multiplet, 2H.
: Example XXIV
N-[3-(2-amino-4-methylthiazole-5-yl)pr~ ]-N'-cyano-N"-[3-(4-morpholino)propyl]guanidine (34d) .' ' .
, . - :, ', : , : .
. . . .;.,. . ' : : ' ~ . : ~
.: ~ : : . ~ - : .
-: . , - ., . . . . -, . :
.: ' ~ ' - - :' - - ' , ~: . . . . . . .
WO91/1~57 PCT/NL91t~W~8:
f~''.
207~ 80 ~ `
To a solution of 1.34 g (0.005 mole) of N-E3-(2-amino-4-met;hylthiazole-5-yl)propyl]-N'-cyano-5-methyl isothioureum ~32c) in circa 50 ml of pyridine 1.44 g (0.01 mole) of 3-(4-morpholino)propylamine is added, then with stirring in a nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl-ether. Subsequently it is recrystallized from a mixture of absolute ethanol and methanol.
10 Yield 48%. Melting point 149.0-151.2C.
H-NMR (D6-DMS0); 1.70-1.90 ppm., multiplet,4H; 2.01 ppm., . singlet, 3H; 2.11-2.70 ppm., multiplet, 8H; 3.00-3.36 ppm., multiplet, 4H; 3.54-3.78 ppm., multiplet, 4H; 6.65 ppm., singlet, 2H; 7.12-7.46 ppm, multiplet, 2H.
Example XXV
__ N-~-3-(2-amlno-4-methylthlazole-5-yl~propyl] N'-c~ano=N"-(3-phenylbutyl)guanidine (34e) __ _ _ _ :. . .... .. . . . . .
To a solution of 1.34 g (0.005 mole) N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum (32c) in circa 50 ml of pyridine 1.499 (0.01 mole) of 4-phenylbutylamine is added, thereafter with stirring in a ; nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl - 25 ether. Subsequently it is recrystallized from absolute ethanol.
Yield 51~. Me1ting point 159.3-161.9C.
`'-;
;
.
.:
' ' ~
.
.
:. . . .
;
.
. :-. . .
WO91~ 7 PCTtNL91/~N~8 20~80~1 .
H-NMR (D6-DMS0): 1.30-1.35 ppm., multiplet, 6H; 1.98 ppm., singlet! 3H; 2.32-2.75 ppm., multiplet, 4H (partially under DMS0): 2.96-3.38 ppm, multiplet, 4H; 6.62 ppm., singlet, 2H; 6.97-7.18 ppm., multiplet, 2H; 7.26 ppm., singlet, 5H.
Example XXVI
N-[3-t2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-N"-__ __ _ _______ _____ __ (3,3-dlphenylpropy ~ uanidine (34f)_ To a solution of 1.34 g (0.005 mole) N-[3-(2-amino-a-methylthiazole-s-yl)propyl]-N~-cyano-s-methylisothioureum (32c) in circa 50 ml of pyridine 2.11 g (0.01 mole) of 3,3-diphenylpropylamine is added, then with stirring in a nitrogen atmosphere for 48 hours there is refluxed. After cooling the reaction mixture is vacuum concentrated, there-after the residue is extracted a few times with diethyl-ether. Subsequently it is recrystallized ~rom absolute ethanol.
Yield 60% Melting point 164.7-168.8-C.
H-NMR (D -DMS0): 1.44-1.82 ppm., multiplet, 2H; 1.92 ppm., . 1 6 singlet, 3H; 2.14-2.50 ppm., multiplet, 2H (partially ; 20 under DMS0); 2.86-3.24 ppm., multiplet, 4H; 3.24-3.60 ppm., multiplet, 2H; 3.98 ppm., triplet (J=8.0 Hz), lH; 6.58 ppm., broad singlet, 2H; 6.86-7.25 ppm., multiplet, 12H.
Example XXVII
,. - - .-N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-~3-(3,4-dichlorophenyl)-3-(2-pyridyl)propyl]guanidine tripicrate(35f) ... ~, . . . . . ~ . , .
' . . . .. ~
'. .
.
, .
.
.:
WO 9l/10657 - PCl/NL91/00008 . ,:; .
- 41 - 2tO741~80 A solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yi)propyl]-NI-cyano-S-methylisothioureum (32c) and 1.41 g (0.005 mole) of 2-[3-amino-1-(3,4-dichloro-phenyl)propyl]pyridine~ in circa 50 ml of pyridine is 5 refluxed with stirring in a nitrogen atmosphere for 72 hours.
After cooling the reaction mixture is vacuum concentrated and the residue is washed a few times with diethyl ether.
Subsequently 25 ml of 6M hydrochloric acid solution is added thereto and there is refluxed for 6 hours. After cooling the 10 reaction mixture is vacuum concentrated and the residue is taken up in circa 25 ml of methanol, thereto 4.5 g of pitric acid in circa 50 ml of hot methanol is added.
Subsequently circa 5 ml of demineralized water is added and the precipitate obtained is filtered off, then 15 it is recrystallized from an ethanol/acetone mixture.
Yield 53%.
lH-NMR (D6-DMS0): 1.59-1.83 ppm., multiplet, 2H; 2.10 ppm., singlet, 3H; 2.30-2.71 ppm., multiplet, 4H; 3.00-3.39 ppm., multiplet, 4H; 4.42 ppm., triplet (J=6.7 Hz), lH; 7.20-8.97 ppm., multiplet, 9H; 8.10-8.31 ppm., multiplet, lH; 8.59 ppm., singlet, 6H; 8.65-8.80 ppm., multiplet, lH; 9.15 ppm., singlet, 2H.
Example XXVIII
N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-(3-phenyl propyl)guanidine dipicrate t35~
A solution of 1.34 g (0.005 mole) of N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum ~32c) and 1.35 g (0.01 mole) of 3-phenylpropylamino in circa 2-[3-amino-1-(3,4-dichlorophenyl)propyl]pyridine was obtained in a modif-ied process as described by A.Buschauer et al. Archiv.der Pharm.,322(3), 165-171 (1989) ~' "`; ~ ' . . : ' :'`;`' :
..
: ' ' - : .
WO9l/1~57 PCT/NL91/~W~8' j .
s l r ~ 4i80~ 42 -50 ml of pyridine with stirring in a nitrogen atmosphere for 72 hours there i.5 refluxed. After cooling the reaction mixture is vacuum concentrated and the residue' is washed a few times with diethylether. Subsequently 25 ml of 6M hydro-. .
chloric acid solution is added and there is refluxed for 6 hours. After coollng the reaction mixture is vacuum con- ;
centrated and the residue is taken up in circa 25 ml of methanol, then 3.05 g of picric acid in circa 50 ml of methanol is added thereto. Subsequently circa 5 ml of demineralized water is added thereto and the precipitate ob-- tained is filtered off,then recrystallized from a methanol/water mixture.
Yield 62%.
H-NMR (D6-DMS0): 1.53-2.20 ppm., multiplet, 4H; 2.07 ppm., ' 15 singlet, 3H; 2.40-2.78 ppm., multiplet, 4H (partially , under DMS0); 3.00-3.76 ppm., multiplet, 4H; 7.00-7.26 ppm., '~ multiplet, 8H; 8.6Z ppm., singlet, 4H; 9.14 ppm., singlet, 2H.
; ExampleXXIX
' 20 N-[3-(2-amino-a-methylthiazo propyl)guanidine dipicrate (35h) A solution of 1.34 g (0.005 mole) of N-~3-(2-amino-4-methyl-thiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum (32c) ' and 1.25 g (0.01 mole) of N-(3-aminopropyl)imidazole in circa 50 ml of pyridine is refluxed with stirring in a . , .
~'; nitrogen atmosphere for 72 hours. After cooling the reaction 'd mixture is vacuum concentrated and the residue is washed a ' few times wlth cold methanol. Subsequently 25 ml of 6M hydro-' ' . ., ~.
~,~ . . . .
~ - .
.~ .~: - , ' .~ , . ': '- . . ' : ... .
..
, WO91/1~57 PCTtNL9l/~H~8 2 0~7`~ ~ -8`~5l ~
_ 43 -chloric acid solution is added thereto and~there is refluxed for 6 hours. After cooling the reaction mixture is vacuum concentrated and the residue is taken up in circa 25 ml o f methanol, thereto 3.05 g of picric acid in circa 50 ml of methanol is added. Subsequently circa 5 ml of demineralized water is added thereto and the precipitate obtained is filtered off, then it is recrystallized from a methanol/water mixture.
Yield 38%.
H-NMR (D6-DMS0); 1.60-1.90 ppm., multiplet, 2H; 2.06 ppm., singlet, 3H; 2.06-2.34 ppm., multiplet, 2H; 2.54-2.98 ppm., multiplet, 4H; 3.14-3.60 ppm., multiplet, 2H; 4.28 ppm., triplet (J=7.2 Hz), 2H; 7.22-7.92 ppm., multiplet, 5H; 8.59 ppm., singlet, 4H; 9.10 ppm., singlet, 2H.
~ , .. . .. . . .
: ~
,: . - - .- :, . .
, ~ :" . . .. - :
WO 91t11K~;7 PCI`/NL91/OOOOf~.~
2 0 7 4 1 8 ~
... . .
Table I H2-activities on the g~ineQ-pig right atrium nr. C ompoun (J p D2 ( ~ 0,1 35d ~H H ~S S,9 35C ~J ~JH NH2 H H/'V~\N 6,4 ~ '.
~H H S
~) ~J H
35b ~ , ,C\ ~, 7,3 `` Cl \~
Cl NH2 ~\H H/~S =\~`l :.. ' NH2 histamine 6,1 .
. :
. ~
Claims (7)
1. A substituted .omega.-aminoalkylthiazole, characterized in that it is a. a N-[.omega.-(thiazol-4 or 5-yl)alkyl]isourea, isothiourea or a guanidine derivative with formula 2, wherein X represents a sulphur atom and Y represents a nitrogen atom or alternative-ly X represents a nitrogen atom and Y represents a sulphur atom, n is 1-6, R1 represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R2 represents a hydrogen atom, a straight or branched-alkyl group with 1-4 carbon atoms or an amino group, Z represents a sulphur atom, an oxygen atom or a NH-group respectively, R3 represents a hydrogen atom, a phenyl or an alkyl group with 1-4- carbon atoms respectively and R4 represents a hydrogen atom, a cyano or a benzoyl group respectively;
b. a N-(.omega.-substituted alkyl)-N'-substituted-N"-[.omega.-(thiazol-4 or 5-yl)alkyl]guanidine with formula 3, wherein X represents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represents a nitrogen atom and Y represents a sulphur atom, n is 1-6, R1 represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R2 repre-sents a hydrogen atom, a straight or branched alkyl group with 1-4 carbon atoms or an amino group, R4 represents hydro-gen, a cyano or a benzoyl group respectively, m is 1,2 or 3, A represents a sulphur or an oxygen atom, a -CH2- or a -CH=
group respectively and Q represents a R-substituted diphenyl-methyl group or a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or Q represents a nitrogen atom substituted with Q1 and Q2, wherein Q1 and Q2 represent whether or not symmetrical R-substituted (.omega.-)-phenyl(alkyl) groups, or Q represents a R-substituted (.omega.-)phenyl(alkyl) group or Q represents a whether or not symme-trical mono-or disubstituted methylidene fragment, wherein R' represents a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or R' represents two whether or not symmetrically with R substituted phenyl groups, wherein R represents hydrogen, alkyl, alkoxy, amino, mono- or dialkylamino, guanidino, nitro, carboxy, carbalkoxy, halogen (fluoro, chloro, bromo, iodo), mono-, di- and triha-logenmethyl or -methoxy (halogen = fluoror chloro, bromo) etc., while in addition the R-substituted phenyl rings may be replaced by a (heterocyclic) (aromatic) ring whether or not R-substituted or by a combination of a (condensed) (aromatic) (heterocyclic) R-substituted ring with one or more (conden-sed) (aromatic) (heterocyclic) rings whether or not symmetri-cally R-substituted.
b. a N-(.omega.-substituted alkyl)-N'-substituted-N"-[.omega.-(thiazol-4 or 5-yl)alkyl]guanidine with formula 3, wherein X represents a sulphur atom and Y represents a nitrogen atom or alternati-vely X represents a nitrogen atom and Y represents a sulphur atom, n is 1-6, R1 represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R2 repre-sents a hydrogen atom, a straight or branched alkyl group with 1-4 carbon atoms or an amino group, R4 represents hydro-gen, a cyano or a benzoyl group respectively, m is 1,2 or 3, A represents a sulphur or an oxygen atom, a -CH2- or a -CH=
group respectively and Q represents a R-substituted diphenyl-methyl group or a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or Q represents a nitrogen atom substituted with Q1 and Q2, wherein Q1 and Q2 represent whether or not symmetrical R-substituted (.omega.-)-phenyl(alkyl) groups, or Q represents a R-substituted (.omega.-)phenyl(alkyl) group or Q represents a whether or not symme-trical mono-or disubstituted methylidene fragment, wherein R' represents a R-substituted (10,11-dihydro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or R' represents two whether or not symmetrically with R substituted phenyl groups, wherein R represents hydrogen, alkyl, alkoxy, amino, mono- or dialkylamino, guanidino, nitro, carboxy, carbalkoxy, halogen (fluoro, chloro, bromo, iodo), mono-, di- and triha-logenmethyl or -methoxy (halogen = fluoror chloro, bromo) etc., while in addition the R-substituted phenyl rings may be replaced by a (heterocyclic) (aromatic) ring whether or not R-substituted or by a combination of a (condensed) (aromatic) (heterocyclic) R-substituted ring with one or more (conden-sed) (aromatic) (heterocyclic) rings whether or not symmetri-cally R-substituted.
2. A process for the preparation of an .omega.-aminoalkylthiazole, characterized in that one prepares a 4- or 5-(.omega.-aminoalkyl)-thiazole derivative with formula 1 in which R1 and R2 have the same meaning as in claim by ring closure of a 2-bromo-.omega.-phthalimidoalkanal (18), a 3-bromo-.omega.-phthalimidoalkan-2-one (24) or a 1-bromo-.omega.-phthal-imidoalkan-2-one (27) with thioformamide, an alkylthioamide or thiourea in dimethylformamide under mild conditions, followed by hydrazinolysis or hydrolysis with diluted hydrochloric acid of the resulting phthalimido derivatives (19, 25 or 28).
3. A process for the preparation of a histamine H2-receptor active compound whether or not in combination with additionally desired biological activity characterized by preparing from a corresponding compound according to formula 1 or 2 or an acid addition salt thereof a compound with a substituted 4- or 5-(.omega.-thiazolylalkyl)guanidine fragment.
4. Medicament, or scientific (pharmacological) adjuvant, characterized in that it contains as the active ingredient a compound according to one of the formulas 2-3 or a compound obtained according to claim 3 or an acid addition salt thereof.
5. Use of a compound or medicament according to one of the previous claims for the treatment of congestive heart diseases whether or not accompanied by heart failure or for the treatment of allergic disorders.
6. A process for the preparation of 2-bromo-.omega.-phthalimido-alkanals characterized by selective .alpha.-bromination of the corresponding .omega.-phthalimidoalkanals with bromine in carbon tetrachloride.
7. 2-Bromo-.omega.-phthalimido-1-alkanals.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9000132 | 1990-01-19 | ||
NL9000132A NL9000132A (en) | 1990-01-19 | 1990-01-19 | NEW THIAZOLE DERIVATIVES. |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2074180A1 true CA2074180A1 (en) | 1991-07-20 |
Family
ID=19856444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002074180A Abandoned CA2074180A1 (en) | 1990-01-19 | 1991-01-18 | Thiazole derivatives |
CA002074175A Abandoned CA2074175A1 (en) | 1990-01-19 | 1991-01-18 | Thiazole derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002074175A Abandoned CA2074175A1 (en) | 1990-01-19 | 1991-01-18 | Thiazole derivatives |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0511270A1 (en) |
JP (2) | JPH05503096A (en) |
AU (2) | AU7064491A (en) |
CA (2) | CA2074180A1 (en) |
IE (2) | IE910172A1 (en) |
IL (2) | IL96998A0 (en) |
NL (1) | NL9000132A (en) |
WO (2) | WO1991010657A1 (en) |
ZA (2) | ZA91418B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0507485A (en) * | 2004-02-05 | 2007-07-10 | Probiodrug Ag | new glutaminyl cyclase inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2636037A (en) * | 1947-10-10 | 1953-04-21 | Sharp & Dohme Inc | 2-amino-4-piperidinoethyl-thiazole |
FR2073427A1 (en) * | 1969-11-28 | 1971-10-01 | Sogeras | 4-methyl-5-ethyl-n-heterocyclic thiazoles - with antianoxic activity |
FR2361111A1 (en) * | 1976-08-11 | 1978-03-10 | Roussel Uclaf | NEW DERIVATIVES OF 5-THIAZOLE ALKYLAMINE, A PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
US4166860A (en) * | 1977-10-11 | 1979-09-04 | William H. Rorer, Inc. | Imidazole amidinoureas for stimulating H2 -receptors |
US4474794A (en) * | 1982-03-19 | 1984-10-02 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N1 -alkenyl (or alkynyl)guanidines and related compounds |
NL8601585A (en) * | 1986-06-19 | 1988-01-18 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | N- (2-SUBSTITUTED ALKYL) -N-IMIDAZOL-4-YL ALKYL GUANIDINE. |
NL8800998A (en) * | 1988-04-18 | 1989-11-16 | Cedona Pharm Bv | PROCESS FOR PREPARING AN SUBSTITUTION OR SUBSTITUTED 4 (5) - (OMEGA-AMINOALKYL) IMIDAZOLE. |
-
1990
- 1990-01-19 NL NL9000132A patent/NL9000132A/en not_active Application Discontinuation
-
1991
- 1991-01-18 AU AU70644/91A patent/AU7064491A/en not_active Abandoned
- 1991-01-18 CA CA002074180A patent/CA2074180A1/en not_active Abandoned
- 1991-01-18 CA CA002074175A patent/CA2074175A1/en not_active Abandoned
- 1991-01-18 JP JP3502574A patent/JPH05503096A/en active Pending
- 1991-01-18 EP EP91902804A patent/EP0511270A1/en not_active Withdrawn
- 1991-01-18 IE IE017291A patent/IE910172A1/en unknown
- 1991-01-18 WO PCT/NL1991/000008 patent/WO1991010657A1/en not_active Application Discontinuation
- 1991-01-18 WO PCT/NL1991/000007 patent/WO1991010656A1/en not_active Application Discontinuation
- 1991-01-18 IE IE017191A patent/IE910171A1/en unknown
- 1991-01-18 AU AU70581/91A patent/AU7058191A/en not_active Abandoned
- 1991-01-18 JP JP3502573A patent/JPH05503694A/en active Pending
- 1991-01-18 EP EP91902805A patent/EP0511271A1/en not_active Withdrawn
- 1991-01-21 ZA ZA91418A patent/ZA91418B/en unknown
- 1991-01-21 ZA ZA91419A patent/ZA91419B/en unknown
- 1991-01-22 IL IL96998A patent/IL96998A0/en unknown
- 1991-01-22 IL IL96997A patent/IL96997A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL96998A0 (en) | 1992-03-29 |
JPH05503694A (en) | 1993-06-17 |
JPH05503096A (en) | 1993-05-27 |
ZA91419B (en) | 1991-10-30 |
CA2074175A1 (en) | 1991-07-20 |
EP0511270A1 (en) | 1992-11-04 |
IE910172A1 (en) | 1991-07-31 |
AU7064491A (en) | 1991-08-05 |
ZA91418B (en) | 1991-10-30 |
EP0511271A1 (en) | 1992-11-04 |
NL9000132A (en) | 1991-08-16 |
WO1991010656A1 (en) | 1991-07-25 |
IE910171A1 (en) | 1991-07-31 |
IL96997A0 (en) | 1992-03-29 |
AU7058191A (en) | 1991-08-05 |
WO1991010657A1 (en) | 1991-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI76795C (en) | Process for the preparation of novel, therapeutically useful 3,4-disubstituted 1,2,5-thiadiazole-1-oxides and -1,1-dioxides and novel intermediates | |
US4560690A (en) | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents | |
NO329617B1 (en) | Thiazole derivatives with CB1 antagonistic, agonistic or partial agonistic activity | |
NO170883B (en) | PROCEDURE FOR PREPARING 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES | |
CA2306811A1 (en) | Piperazine compounds and medicinal use thereof | |
NO158419B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,2-DIAMINOCYCLOBUTEN-3,4-DIONES. | |
CA2185082A1 (en) | Azole derivatives, their use, production and usage | |
KR20020003559A (en) | INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF | |
US6586456B1 (en) | Aminothiazole derivatives and their use as CRF receptor ligands | |
CA1310966C (en) | Substituted 1-(h-imidazol-4-yl)alkyl-benzamides | |
NO151322B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2 (5-METHYL-4-IMIDAZOLYL-METHYLTIO) ETHYLAMINO (NO2-HETEROCYCLIC GROUP) COMPOUNDS | |
HU182461B (en) | Process for producing new h-2 down-receptore antagonistic thiazole derivatives | |
NO885117L (en) | SUBSTITUTED HYDROXYLAMINES. | |
EP0234011A1 (en) | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | |
US4935424A (en) | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents | |
CA2074180A1 (en) | Thiazole derivatives | |
US4692531A (en) | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity | |
DD295373A5 (en) | PROCESS FOR PREPARING ALPHA-CYAN-BETA-OXOPROPIONAMIDES | |
Suzuki et al. | Syntheses of 2-Aryl-4-(3-thienyl) imidazole Derivatives with Antiinflammatory Preperties | |
CS197238B2 (en) | Method of producing novel acylated derivatives of 2-amino thiazole | |
SU535906A3 (en) | Method for preparing 2-aminothiazole derivatives | |
JPH0578339A (en) | Intermediate compound | |
NO122530B (en) | ||
NO148556B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE TRIAZINONES. | |
KR870000924B1 (en) | Process for preparing 2-(n-substituted guanidino)-4-heteroarylthiazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |